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Abstract
Patient characterization is the key for the successful treatment of type
1 diabetes mellitus. This characterization is currently done heuristically
by physicians over continuous clinical visits to the patient. Improving
diabetes care has been identied as a priority in national and international
health programs. In this context, attention has been focused on automated
control strategies of plasma glucose -the so called Articial Pancreas-, and
signicant investment has been done by governments and pharmaceutical
companies to its development. Mathematical modeling of the patient is
crucial in this aspect, and the parametric characterization of the patient
in the mathematical model has proven to be a dicult task to accomplish.
In this thesis, identiability studies have been performed on several
models present in literature. A critical review of the models based on their
identiability has been performed, and a new model has been proposed to
overcome the problems found. A clinical protocol has been developed to test
this methodology, based on home continuous glucose monitoring of subjects
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Chapter 1
Glucose Control and Diabetes
Glucose is the main source of energy for the metabolism of the cells. In
particular, brain metabolism is strictly dependent on glucose supply from the
bloodstream. Thus, it is not surprising that regulation of glucose metabolism
in the human body implies many dierent control systems, relating several
hormones and organs. Indeed, the hormonal interplay regulates glucose
production (basically in the liver and, to a lesser extent, in the kidney) and
glucose uptake from tissues, as to maintain blood glucose concentrations in
a narrow range.
However, there exist a number of pathologic conditions that aect glucose
metabolism, the most famous (and frequent) being Diabetes Mellitus (DM).
This chapter exposes the most important cycles and reactions that take place
in the organism in order to maintain the glucose homeostasis, and discusses




In humans plasma glucose is normally maintained within a narrow range
(approximately 65-140 mg/dl), in both the fasting and fed state, due to a
tightly linked balance between glucose production (basically from the liver)
and utilization (from all the other tissues: the muscle, the adipose tissue
and the brain). This is critical in patient's health, as explained by the
devastating eects of deregulation of glucose metabolism. Indeed, excessive
increase in plasma glucose concentration (diabetes) over years is responsible
for a 2-5 fold increase in cardiovascular morbidity and mortality among
diabetic people as compared to the general population. On the other hand,
maintenance of plasma glucose above the threshold of hypoglycemia is critical
for survival of the whole body. This is because glucose oxidation normally
provides more than 90% of the energy needed for brain function and since
the brain cannot synthesize glucose, and has reserves sucient for only a few
minutes, its function is almost totally dependent upon a continuous supply of
glucose from the arterial circulation. Thus, it is not surprising that control
mechanisms which maintain plasma glucose homeostasis are complex and
that organs which normally release glucose into the circulation, namely liver
and kidney, play a key physiological role in supporting brain function. The
central nervous system and several hormones (insulin, glucagon, epinephrine,
norepinephrine, GH and cortisol) participate into the regulation of glucose
metabolism. However, as explained below, insulin is certainly the main actor.
For more information about glucose metabolism check Williams and Pickup
[105].
1.1.1 Role of Insulin
Insulin is the main regulatory hormone used in the body for reducing the
glucose concentration in blood. Its main function is to enable the glucose
absorption from blood by muscles and liver, and then convert that glucose
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into glycogen. It is also the hormone that controls the absorption of glucose
by the adipose tissue, and then stores that glucose as triglycerides. It has
also an eect over the metabolism of many nutrients, as carbohydrates and
proteins.
Insulin is secreted from the pancreas, in the zones called Langerhans
islets, and specically by the β-cells. The Langerhans islets are regions of
the pancreas where the hormones related with the glucose homeostasis and
metabolism are produced. Four main types of cells can be found: α-cells
producing glucagon; β-cells producing insulin and amylin; δ-cells producing
somatostatin; PP cells producing pancreatic polypeptide.
In both the fed and fasted states, insulin is foremost among the
factors that regulate glucose production and utilization. Under normal
circumstances, an increase in plasma glucose concentration such as after
carbohydrate ingestion, is accompanied by a prompt increase in insulin
secretion. The resultant increase in plasma insulin concentration accelerates
glucose utilization and suppresses production. Conversely, a decrease
in plasma glucose concentration is accompanied by a decrease in insulin
secretion; the resultant decrease in circulating insulin concentration causes
a decrease in glucose utilization and an increase in endogenous glucose
production.
Hence, plasma insulin levels change according to the metabolic status,
ensuring the balance between glucose production (by the liver) and glucose
utilization (by the other tissues), and resulting in stability of plasma
glucose concentrations. Rates of glucose production and utilization are
also inuenced by the so called counterregulatory hormones glucagon,
adrenaline, cortisol and growth hormone independent of changes in insulin
concentration. All of these hormones have biological eects that can oppose
those of insulin and are involved in physiological responses to prevent/limit
hypoglycemia.
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Post-absorptive and fasting state
The four-hour to six-hour interval following ingestion of a meal is generally
referred to as the post-absorptive state. At this point, plasma glucose
concentrations average 80 to 90 mg/dl, and rates of glucose utilization are
approximately 2 mg/kg/min. At least 50% of whole body glucose utilization
is due to noninsulin-dependent uptake of glucose from the brain. The formed
elements of the blood, renal medulla and muscle, metabolize glucose to
pyruvate and lactate. These substances can be released into the circulation
and serve as substrates for gluconeogenesis. In the postabsorptive state,
insulin sensitive tissues such as muscle, adipose tissue, and liver account for
less than 30% to 50% of overall glucose utilization. Following meal ingestion,
however, liver and muscle take up glucose to replenish their glycogen stores
and transiently increase their utilization of glucose.
If fasting is prolonged beyond the post-absorptive period, plasma glucose
concentrations decrease over the succeeding 48 to 78 hours to reach a nadir
of approximately 45 to 60 mg/dl that can be maintained for several weeks.
Plasma free fatty acids and ketone body concentrations increase several-fold,
reaching levels of 1 to 2 mmol/l by 72 hours. Glucose utilization decreases
during this time to approximately 1 mg/kg/min and remains constant
thereafter. These changes are in large part due to decreases in plasma insulin
concentration that permits accelerated lipolysis with increased ketone body
formation. Muscle and other tissues become progressively more dependent
on free fatty acids and ketone bodies. Also, ketone bodies replace glucose as
the predominant fuel for neural tissues, thus reducing the obligatory glucose
uptake by the brain.
Absorptive state
The increase in plasma insulin concentration that occurs immediately
following a meal suppresses endogenous glucose production, an eect also
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mediated by the increased plasma glucose concentration. Consequently,
hepatic glycogenolysis is suppressed and glycogen deposition stimulated.
Approximately 50% of an oral glucose load is taken up by the liver and
the remaining by peripheral insulin-sensitive tissues. Three to four hours
following meal ingestion, the liver again releases glucose into circulation.
Ultimately, the rate of glucose released equals the rate of glucose utilization
so that plasma glucose concentrations are maintained stable.
Nearly all tissues, to varying degrees, oxidize glucose to derive energy
for metabolic demands. Yet only the liver and kidney release glucose. This
release results from the presence in these organs of glucose-6-phosphatase
which liberates glucose into the bloodstream. The liver and kidney do not,
however, contribute equally to post-absorptive glucose homeostasis. It is
generally believed that the liver makes the major quantitative contribution
during this state, while the kidney plays a minor role.
1.1.2 Role of Glucagon
In the experiments of Banting and Best that led to the discovery of insulin
in 1921 [4], a contaminant in pancreatic extracts was reported that caused
a transient increase in blood glucose. Nevertheless, the hypoglycemic eect
of the extract was sustained and predominated. Insulin was isolated from
the extract and went into immediate use for treatment of diabetes. Working
in the shadow cast by the discovery of insulin, Murlin and colleagues [42]
[58] went on to dene the hyperglycemic factor in pancreatic extracts. They
wrote in 1923: There are two substances in these aqueous extracts, one of
which lowers the blood sugar and the D:N ratio and raises the R.Q. (insulin),
the other raises the blood sugar of both normal and depancreatized animals.
... Based on their observations, these investigators proposed the existence
of a second hormone secreted by the pancreas. They proposed the name
glucagon, a contraction of the words glucose and agonist, for this putative
hormone.
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The full signicance of glucagon in physiology and diabetes was not
appreciated until the development of the radioimmunoassay, which made
plasma glucagon measurement routine. Exercise has been used as a
physiological stimulus to challenge the glucoregulatory system in a dog model
and to dene the roles of glucagon, demonstrating its important role in
maintaining blood glucose. It was shown that glucagon has mainly an hepatic
eect, being the key to both the glycogenolytic and gluconeogenic responses
to exercise [100]. This means that it stimulates glucose production by the
liver, allowing for compensation of increased glucose uptake from the muscle
during periods of physical activity, therefore preventing plasma glucose fall
to hypoglycaemia. Indeed, several studies have demonstrated that glucagon
secretion, along with suppression of endogenous insulin production, is the
rst physiological counterregularoy response to impending hypoglycaemia
[56]. Disfunction of this counterregulatory system is responsible for the
burden of hypoglycemia in people with diabetes [19].
1.1.3 Role of Epinephrine
Epinephrine, also known as Adrenaline, is a hormone and neurotransmitter
secreted by the adrenal glands. Catecholamines (mainly adrenaline) appear
to play a key role in counterregulatory response to hypoglycemia. In fact,
blockade of their eects causes severe hypoglycemia despite increases in other
counterregulatory hormones, particularly glucagon. In contrast to glucagon
which exerts its eects exclusively on glucose production, catecholamines
exhibit multiorgan eects, including suppression of endogenous insulin
secretion, stimulation of hepatic and renal glucose production, inhibition of
peripheral glucose utilization, and stimulation of lipolysis. Like glucagon, it
is likely that the sustained increase in glucose production is primarily due to
stimulated gluconeogenesis ([47]).
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1.1.4 Role of slow-acting Hormones
Growth hormone and cortisol are referred to as slow-acting hormones
because their eects become evident after a few hours of their increase
in plasma. Therefore, the counterregulatory role of these hormone is
appreciated only after 3 hours of hypoglycemia. Both cortisol and growth
hormone are critical to counterregulation because absent response of either
one of these two hormones is not compensated by even larger responses
of other hormones, including the rapid-acting hormones glucagon and
adrenaline.
1.1.5 Eectiveness of Glucose Control
Blood glucose control has two attributes that make it very eective. First,
there is redundancy of control due to multiple layers of the glucoregulatory
response. Changes in pancreatic islet glucagon and insulin secretion normally
prevent hypoglycemia. Should the response of the pancreas be inadequate,
other controllers (e.g., catecholamines, cortisol, growth hormone, and glucose
autoregulation) are in place to prevent a deeper fall in blood glucose. Second,
there is distribution of control that includes nutrition, liver function, and
energy metabolism. Glucose delivery is a function of glucose concentration
and vascular regulation. The ability of the gut to supply glucose in the
postprandial state and the liver to do so in the postabsorptive state maintains
blood glucose concentration. By doing so, these organs sustain glucose
delivery and exert control over peripheral (mainly muscle) glucose uptake.
In fact, in the postabsorptive state the rate that glucose is released from
the liver is the most sensitive regulator of muscle glucose uptake. With
prolonged exercise or mild hyperinsulinemia, the muscle is highly permeable
to glucose but muscle glucose uptake still declines. During prolonged exercise,
the glycogen-depleted liver cannot sustain blood glucose.
With iatrogenic hyperinsulinemia (i.e., treatment of diabetes), the release
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of glucose from the liver is suppressed, causing a decrease in blood glucose.
In short, factors that control the release of glucose from the liver such as
insulin, glucagon, and nutritional state are part of distributed control.
1.2 Diabetes Mellitus
For 2,000 years diabetes has been recognized as a devastating and deadly
disease. In the rst century A.D. a Greek, Aretaeus, described the destructive
nature of the aiction which he named diabetes from the Greek word for
siphon. Eugene J. Leopold in his text Aretaeus the Cappodacian describes
Aretaeus' diagnosis: ...For uids do not remain in the body, but use the
body only as a channel through which they may ow out. Life lasts only
for a time, but not very long. For they urinate with pain and painful is the
emaciation. For no essential part of the drink is absorbed by the body while
great masses of the esh are liqueed into urine.
Physicians in ancient times, like Aretaeus, recognized the symptoms of
diabetes but were powerless to eectively treat it. Aretaeus recommended
oil of roses, dates, raw quinces, and gruel. And as late as the 17th century,
doctors prescribed gelly of viper's esh, broken red coral, sweet almonds,
and fresh owers of blind nettles.
In the 17th century a London physician, Dr. Thomas Willis, determined
whether his patients had diabetes or not by sampling their urine. If it had a
sweet taste (due to a phenomenon known as glycosuria, which occurs when
blood glucose goes up above the threshold of 180 mg/dl) he would diagnose
them with diabetes mellitus- honeyed diabetes. This method of monitoring
urine glucose went largely unchanged until the 20th century.
In the early 20th century, diabetologists such as Dr. Frederick Allen
prescribed low calorie diets-as little as 450 calories per day for his diabetic
patients. His diet prolonged the life of people with diabetes but kept them
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suering from near starvation. In eect, people with diabetes suered a
painful wasting death. Then in 1921 something truly revolutionary occurred
in Ontario, Canada. A young surgeon Frederick Banting, and his assistant
Charles Best, kept a severely diabetic dog alive for 70 days by injecting it with
a murky concoction of canine pancreas extract. With the help of Dr. Collip
and Dr. Macleod, Banting and Best administered a more rened extract of
insulin to Leonard Thompson, a young boy dying of diabetes. Within 24
hours, Leonard's dangerously high blood sugars had dropped to near normal
levels. Until the discovery of insulin, most children diagnosed with diabetes
were expected to live less than a year. In a matter of 24 hours the boy's
life had been saved. News of the miracle extract, insulin, spread like wildre
across the world.
Since insulin's discovery, medical breakthroughs continued to prolong and
ease the lives of people with diabetes. In 1935 Roger Hinsworth discovered
there were two types of diabetes: insulin sensitive (type 1) and insulin
insensitive (type 2). By dierentiating between the two types of diabetes,
Hinsworth helped open up new avenues of treatment. Indeed, type 1 and type
2 diabetes are characterized by dierent pathophysiologic processes, resulting
in dierent therapeutical approaches.
In the last decades it has become a major health problem worldwide.
Its impact all over the world, and especially in the developed countries, has
alarmed the health organizations in many countries, and major eorts are
being performed to overcome this threat. Scoping into the future is even
more shocking. In gure 1.1 the estimate of diabetes prevalence per country
in 2010 can be seen. The increase in population combined with aging of
people makes the problem of diabetes to get into epidemic proportions in the
next decades, as can be seen in gure 1.2.
Insulin has a major importance in treatment of diabetes. It is usually
delivered subcutaneously, which delays the eect of the insulin in the blood as
compared with to natural insulin in healthy persons that is secreted directly
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Figure 1.1: Prevalence estimates of diabetes (29-70 years old) in 2010 [39]
Figure 1.2: Prevalence estimates of diabetes (29-70 years old) in 2030 [39]
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into the circulatory system. Human insulin is found in what is called hexamer
form, in which there are six insulin molecules aggregated by means of a zinc
atom. This can be seen in gure 1.3, where every twisted gure is a single
monomer of insulin, and the six of them and the nucleus form the whole
molecule.
Figure 1.3: Structure of insulin in its hexamer form [15]
Subcutaneous absorption of insulin in the hexamer form is really slow,
and it usually has to dissociate into monomers to be able to pass through
the subcutaneous tissue into the bloodstream. The most stable form of
insulin (human insulin) is the hexamer form, and that is the way is stored for
Diabetes treatments, but insulin analogs have been developed in recent years,
which change their most stable form to monomer or dimer (intermediate
stage between monomer and hexamer). The fact that their most stable form
is monomer form makes these insulin analogs to be much faster absorbed than
human insulin, and that has made insulin treatments much more exible.
There are two main types of diabetes mellitus. Type 1 diabetes is
characterized by absolute insulin decit, due to the autoimmune destruction
of the pancreatic beta cells. Hence, the treatment for people with type 1
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diabetes is necessarily the replacement of the endogenous insulin secretion
by means of the administration of exogenous insulin. On the other hand, type
2 diabetes is the result of two concomitant alterations: 1) insulin resistance
(i.e. the liver and the muscle have less than normal sensitivity to the insulin
action); 2) impaired beta cell function (i.e. the physiological response of the
beta cell to a meal is lost, as well as its ability to compensate for insulin
resistance). This results in relative insulin decit, which can be approached
with several non pharmacological (physical exercise) and pharmacological
measures. However, the natural history of type 2 diabetes is characterized
by progressive lost of the beta cell function overtime, nally leading to a
condition of absolute insulin decit requiring replacement with exogenous
insulin.
There are other types of DM, like the pathologies that are induced by
infections or endocrinopathies, and they can be of transitional character,
like the gestational diabetes occurring in pregnant women, or remain chronic
for the patient, but these sorts of DM are not going to be studied in here.
Diabetes type 1 and 2 will be explained in detail in chapters 1.2.1 and 1.2.2.
The degree of metabolic control obtained by people with diabetes can be
measured by the concentration of glycated hemoglobin in blood, also called
HbA1c. Hemoglobin is the protein used to transport oxygen though the
circulatory system. In presence of glucose it undergoes a non-enzymatic
reaction, becoming glycated. This transformation is in relation to the average
concentration of glucose in blood, due to the half-life of red blood cells, it
is representative of mean blood glucose concentrations during the past 8-12
weeks. For the record, a healthy person has a 5.5% of hemoglobin in glycated
state, while a diabetic patient is considered to be under control if its HbA1c
is under 7%.
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1.2.1 Diabetes type 2
Diabetes Mellitus type 2 is the most extended sort of diabetes, and accounts
for 85% of cases in developed countries. It is related to various clinical
risk factors such as increasing age, obesity, and racial and geographical
characteristics. It is the diabetes type 2 the one that threats with epidemic
proportions worldwide. Its onset peak is around 50 years and almost 80% of
type 2 diabetic subjects are obese.
Two main defects characterize the pathophysiology of T2 DM:
1. Beta cell dysfunction. Usually the deterioration aects initially the
prandial insulin secretion. Indeed, the so called rst phase of insulin
response is lost early on in the natural history of the disease, resulting in
post-prandial hyperglycemia. However, Beta cell function deteriorates
progressively overtime, leading to an absolute insulin decit.
2. Insulin resistance. Hepatic insulin resistance causes excessive glucose
production, contributing to fasting hyperglycemia. Peripheral (muscle)
insulin resistance leads to inecient glucose utilization. It is related to
obesity and physical inactivity, both related to hepatic and intra-muscle
lipid accumulation. However, insulin resistance is not able 'per se' to
cause diabetes. Indeed, the normal beta cell can compensate for insulin
resistance and this is the reason because obese people are not always
diabetic.
Diabetes develop when defective beta cell cannot compensate for insulin
resistance.
A wide therapeutic armamentarium is available for the treatment of type
2 diabetes mellitus. Unfortunately deterioration of β-cells does not stop with
any drugs, and diabetic patients type 2 will become dependent of exogenous
insulin, just as type 1 diabetic people are. The treatment related to insulin
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administration will be explained in chapter 1.2.2.
1.2.2 Diabetes type 1
Aetiology
This type of diabetes is an autoimmune disease, and as said before, idiopathic,
meaning that the disease arises spontaneously, or from an obscure or
unknown cause. It is related to a low level of insulin in blood, which causes
the blood glucose to be constantly in high levels, which can cause severe
symptoms including ketoacidotic coma in some patients. The disease is
also suddenly discovered in most patients, who are usually lean people that
present recent loss of weight. Patients with Diabetes Mellitus Type 1 presents
markers of antibodies denoting the destruction of β-cells. This destruction
causes the low insulin levels that lead to the rest of the symptoms, such
as constant high blood glucose concentrations and ketoacidotic coma in the
extreme cases. The aetiology (chain of events leading to diagnosis) of DM1
is complex and not completely understood, but it is supposed to imply both
genetic predisposition and environmental factors, as can be seen in gure 1.4.
Physiopathology
The problem for the patients of DM1 is then that they do not have an
endogenous (proceeding from within) insulin secretion system and this insulin
has to be given in an exogenous (coming from outside) way.
Normal non-diabetic subjects maintain plasma glucose below 100 mg/dl
during fasting state, and below 140 mg/dl in the post-prandial period.
During fasting, maintenance of normoglycaemia is possible because of the
continuous release of insulin from the pancreas which restrains hepatic
glucose production and prevents hyperglycaemia. At meal times, the normal
14
Figure 1.4: Aetiology of type 1 diabetes [105]
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pancreas releases insulin very rapidly in response to meal ingestion as
indicated by the early and elevated insulin peak appearing in peripheral
plasma. It can be estimated that the corresponding portal plasma insulin
concentrations of the prandial peaks are nearly twice as elevated. This
is what is needed in terms of insulin delivery to prevent post-prandial
hyperglycaemia.
However, of similar importance is the rapid decrease of plasma insulin
60-90 minutes after meal ingestion, preventing hypoglycaemia in the post-
prandial period. Also, the fact that between meal plasma insulin is at
and peakless is a key factor in the prevention of interprandial and fasting
hypoglycaemia, particularly at night.
This model of natural insulin dynamics should be imitated whenever
insulin has to be replaced. Given that Diabetes Mellitus type 1 is
characterized by absolute insulin decit and therefore the only treatment
is its replacement, the logical strategy to palliate the eects of the disease is
to mimic the non-existent insulin secretion rate.
Current strategies for insulin replacement
In the early 1980s human insulin was introduced to the market by drug
companies substituting animal insulin emphasizing the belief that diabetic
people should be treated with naturally secreted insulin from the human
body. Better glycaemic control was expected in people with diabetes using
human compared with animal insulin. This was not the case, since no single
advantage could be proven for humans versus animal insulin ([89]).
However, the positive aspect of human insulin was the innovative
technology used for its production (DNA-recombinant technique) versus
the traditional insulin extraction method from animal pancreata. This
new technique helped to develop a number of insulin analogues. Major
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eorts were started to modify the human insulin and develop modied
insulins for administration to diabetic subjects. Slow and rapid acting
insulin analogues are available now for the dierent stages of the treatment
of diabetes. Slow acting insulins (up to 24h permanence in blood) can
be used for substituting the at insulin level in the interprandial periods.
Fast acting insulin analogues (1-2 hours life cycle) on the contrary, may be
used to replicate the postprandial insulin peaks of the (non-existent) insulin
secretion.
Regardless of the system of glucose measurement or the way insulin is
delivered, the control philosophy for glucose control in DM1 is to replicate the
insulin secretion pattern of the non-diabetic person. As already explained,
in the fasting and post-absorptive state, insulin secretory rate is regulated
in a feedback fashion by plasma glucose levels. This is known as basal
insulin, which modulates hepatic glucose production to exactly compensate
for peripheral glucose utilization maintaining plasma glucose concentrations
in a very narrow range. In the post prandial state, beta cells increase insulin
secretion to cope with glucose absorption from the gut into the bloodstream.
This is called prandial insulin secretion, which results in high plasma insulin
concentrations that suppress hepatic glucose production (unnecessary since
glucose is being absorbed from the gut) and increase glucose disposal into
the liver and the muscle, allowing for very small meal-induced uctuations
in plasma glucose concentrations. It should be noted that the feedback
mechanisms regulating insulin secretion, probably rely on measurement
of glucose concentration in the blood (or in some compartment in fast
equilibrium with the blood). Thus, mimicking physiological insulin secretion
must translate into replacement of both basal and prandial components, and
ideally it should be based on measurements of blood glucose concentrations
and on insulin infusion directly into the blood stream.
However, for practical reasons in clinical practice, insulin is usually
injected subcutaneously. This introduces a delay between insulin injection
and insulin action, which represents the time needed for the absorption
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of insulin from the subcutaneous tissue into the blood. This lag time
depends on the chemical properties of the insulin injected (which inuence
its rate of absorption) and is one of the barriers to the development of the
articial pancreas. The insulin molecule has been modied in order to obtain
preparations suitable for more accurate insulin replacement ([84]). Indeed,
current strategies for insulin administration use a long-acting insulin analogs
(the molecule has been modied to ensure a constant 24 hour absorption
from the subcutaneous tissue, following injection) for basal replacement and
a fast acting insulin analogs (the molecule has been modied to accelerate
its absorption from the subcutaneous tissue) for prandial requirements.
This therapy is called basal-bolus strategy, and it is clearly limited by
the pharmacokinetics of insulin, and leaves no possibility of reaction to
unexpected events, such us too low absorption rate of glucose, or sudden
increase of insulin sensitivity of the patient.
Figure 1.5: Insulin pumps [54]
Subcutaneous insulin pumps (as shown in gure 1.5) traditionally use
basal-bolus strategy, but the possibility of adjusting the insulin delivery rate
at any time rises scenarios of a closer control. The main advantages of using
Continuous Subcutaneous Insulin Infusion (CSII) are:
1. Use of rapid acting analogs both for meal insulin and basal insulin.
Indeed, they show better reproducibility of subcutaneous absorption
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as compared to long acting insulins resulting in lower variability.
2. Possibility to adjust basal insulin requirements to the subject
needs (ex circadian variations in insulin sensitivity). This is not
possible with long acting insulins with `xed' pharmacokinetics and
pharmacodynamics.
These new CSII scenarios require of a more ecient glucose measuring
system as well, and the recent subcutaneous real-time glucose monitors, like
the guardian real-time glucose monitoring system from Medtronic shown in
gure 1.6, provide this continuous monitoring required to close the control
loop.
Figure 1.6: Guardian Real-Time Glucose Monitoring System from Medtronic
[54]
Given the chance to read glucose in real-time and act over it with (at
least) one control action, which is the insulin infusion, it is dened a control
system, and there are several control laws that can be applied to create a
tighter control of blood glucose than trying to mimic the behavior of the
physiological insulin production rate. The natural physiological control is
impossible to obtain with the subcutaneous infusion of insulin. However, the
presence of continuous sensors, even though the uncertainty that present,
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opens the possibility of designing new control strategies that will stabilize
glycaemia in diabetic patients.
Even though the simplications performed to the real model are strong,
a reliable control law can be implemented and tested in real patients. This
control problem has been a matter of research for over 40 years, and it is still
going on. The product that is edxpected from the design and implementation
of the control law that is to replace the damaged β-cells in the pancreas is
called Articial Pancreas, and it is the framework of research this thesis is
placed in.
1.3 Articial Pancreas
Over the last 30 years, even with the availability of new insulin preparations
with more physiological proles, continuous administration systems aimed at
emulating endogenous insulin secretion, and new education strategies, there
is still no universal, ecient and safe system able to normalize the glucose
levels of diabetic patients. Progress with enzyme electrodes in the 1970s
[104] allowed for the emergence of continuous glucose monitoring (CGM),
and for the subsequent development of the rst prototypes of glucose-sensor
controlled insulin infusion systems, by dierent groups ([1] and [2]).
The next two decades saw huge progress in the development of continuous
glucose sensing. Research focused on the skin as an appropriate candidate
for direct glucose measurement. Indeed, the subcutaneous tissue is easily
accessible for sensor implantation and measurement of glucose in the
interstitial uid, with fewer problems as compared to the intravascular
space. The amperometric glucose-sensing technique was rened and this
process culminated, in 1999, with the development and FDA approval of the
CGMS R©, the rst commercial CGM device [53]. Since then, technological
progresses have fueled research on closed-loop glucose control systems using
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the subcutaneous route (see below), for eective treatment of diabetic
subjects.
Preliminary studies using o-the-shelf insulin pumps and subcutaneous
continuous glucose monitoring (CGM) sensors have suggested that, in
research settings, closed-loop systems that automatically dispense insulin
can achieve better control of glucose levels than open-loop systems in which
a person makes dosing decisions [92]. Such promising results prompted the
Juvenile Diabetes Research Foundation (JDRF) to push the research forward
by launching its Articial Pancreas Project 4 years ago, and the US Food and
Drug Administration (FDA) to designate the articial pancreas as a priority
within its Critical Path Initiative. However, so far only a few prototypes
have been developed and tested in controlled clinical settings. In fact, several
challenges do still exist:
1. Coping with big disturbances aecting the system, such as meals, stress
and exercise
2. Robustness face to the great variability of patient's physiological
behavior
3. Accuracy and reliability of continuous glucose monitors, that must be
improved to a higher degree
4. Safety of insulin pumps and detection of faults
5. Adequate correction for the slow responsiveness of controllers due to
delays in the control loop (see below)
Control of post-prandial glycaemic excursions is certainly a key issue in
the articial pancreas. Indeed, meals are one of the major perturbations to
counteract and the main challenge found in current clinical validations of the
few existing prototypes of closed-loop glycaemic control systems. This thesis
focus on this issue, aiming at the development of new feedback strategies for
post-prandial glycaemic control.
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1.3.1 Current state of development
The rst experiment conducted closing the control loop in a patient with
diabetes can be traced back to 1964 by Kadish [41]. It was the rst trial to
control the blood glucose with a continuous glucose monitor, and the control
algorithm was just an `on-o' system with constant supervision of doctors,
and the control action (insulin) was delivered in an intravenous way, which
minimizes the delays related to insulin transport in tissues.
In 1974 an `articial endocrine pancreas' was developed simultaneously
by two dierent researchers, Albisser [1] and Pfeier [72], which led to the
rst commercial device that emulated an articial pancreas: The Biostator.
The device implemented a complex algorithm aiming to prevent postprandial
hyperglycaemia, but it was still a bulky machine (gure 1.7) with need of
constant supervision and none at all designed for an independent use.
As already said, considerable improvement has been made in the
technology of glucose monitors for the past 20 years, and insulin pumps
have been developed and proven to be reliable and to improve life quality for
diabetic patients, as shown by Pickup [73]. The use of continuous insulin
infusion coupled with subcutaneous aims to solve the main problem the
Biostator supposed, its low manageability, but it adds new delays to the
control loop, which makes the algorithms needed much more complicated.
The classication of closed-loop systems based on the body interface, and
thus related to its average delay stays as follows:
• Intravenous measuring and intravenous insulin delivery. This
option is the most invasive system, and it represents the minimum delay
possible from the glucose measuring to its response (about 30 minutes).
A revision of the control algorithms used in this paradigm was done
by Parker [69]. Its application is unfeasible in clinical practice and
might be used, in the near future, only in critical patients and hospital
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Figure 1.7: Biostator designed by Pfeier [72]
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treatments (in contexts where invasive techniques do not constitute a
barrier to its implementation). The Biostator is the main example for
this sort of interface.
• Intravenous measuring and intraperitoneal insulin delivery.
Implantable insulin pumps have been used for intraperitoneal (into the
abdominal cavity) infusion, which has many of the advantages of the
full-intravenous interface. However, it still is invasive and adds the
delay related to the absorption of the insulin.
• Subcutaneous measuring and subcutaneous insulin delivery.
It is the less invasive option but also the choice that adds the largest
delays to the control loop. This system is the more suited for long time
treatments, and is the one that is going to be studied in detail in this
thesis.
The increasing delay added by the less invasive interfaces is a present problem
anytime designing a controller for blood glucose. Revision of the main
drawbacks and advantages for every method was done by Hovorka [33], and
the delays present in every sort of control system can be seen in gure 1.8.
Other possible classication for closed-loop control in diabetes will be
regarding the control algorithm implemented:
• PID control. The classical approach control of Proportional-Integral-
Derivative (PID) control is the broadest implemented control algorithm
in industrial applications due to its simplicity and the fact that tuning
algorithms for the controller have been developed for decades.






Where IIR represents the insulin infusion rate, Kp, Kd and Ki are
the parameters of the controller (to be determined), G is the measured
glucose, and Gt is the target glucose. Due to its simplicity, many times
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Figure 1.8: Delays related to the interface of the articial pancreas system as
stated by Hovorka [33]. s.c. stands for the subcutaneous route, i.p. stands
for the intraperitoneal route and i.v. stands for the intravenous interface.
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the PID gives the base structure to the controller, and many heuristic
methods make the controller an expert controller. Marchetti [52] for
example, developed one of these algorithms for type 1 diabetic patients
and Chee [16] did it for critically ill patients.
• State-feedback control. The so called Optimum control
methodology has been used to design algorithms as a feedback of the
state of the model considered. Palumbo [65], for example, used this
approach to design a controller for a Delayed Dierential Equation
model of the glucose regulation system.
• Model predictive control (MPC). MPC is a rather more complex
control philosophy, based on optimization methods to nd the optimum
input that leads the controlled variable to the desired reference in a
target time. It is, as well as the PID controller, widely implemented in
industries, and the tuning algorithms are very ecient and have been
rened for the last decades. A complete overview for the development
of the algorithm and its impact on industry was performed by Camacho
and Bordons [14]. In the context of articial pancreas MPC is the most
applied method of control, and several controllers have been developed,
such as the one of Parker [68], or the one implemented by Hovorka
[34], which was tested in its application on critical patients by Plank
[74], showing that patients were more often within the glucose target
range than with the usual therapy, and that hypoglycemia episodes
were avoided completely by using the MPC controller.
About the optimum algorithm to be chosen in order to control a determined
patient, the answer is not clear. Despite MPC methodology has been the
most used option, it is mathematically proven that if the model is close
enough to reality, the feedback of the state is the most robust and fastest
control possible. That raises the question of whether the models used are
reliable or useful, and how much should we deepen in the matter of modeling,
or just use impulse and step models, as many MPC controllers do. The
question of modeling is explained in depth in chapter 2.
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The last classication of articial pancreas systems is regarding the
situation of the patient during the control, or the population that the system
aims to control:
• Pregnant woman transitional diabetes. Gestational diabetes has
been studied from the point of view of articial pancreas in several
works. Murphy et al. [59] showed the eectiveness of continuous
glucose monitoring in pregnant women with diabetes, and Hernando
et al. [30] used algorithms based in diabetic models to plan insulin
therapy. No specic controllers have been designed for this particular
case.
• Critical patient control. Critical patients are monitored in detail,
not only in glucose, but also in many other important measures of
body functions, which are intended to be as controlled as possible.
This fact gives the opportunity to test many controllers designed for
glucose regulation. The previously mentioned controller of Chee et al.
[16] and the one designed by Hovorka's group in Cambridge [74], are
examples of controllers used to maintain the glucose homeostasis in
intensive care unit patients.
• Overnight fasting control. Overnight period is usually related
to a natural reduction of the sensibility to insulin, and the lack of
consideration of this eect creates an increase in blood glucose that is
commonly known as Dawn eect. Hovorka's group, for example, has
achieved great success in controlling this kind of behavior by means of
glucose monitoring and MPC controllers both with subcutaneous and
intravenous interfaces [86].
• Postprandial control. The main disturbance to blood glucose control
is the absorption of glucose from the gut. The postprandial blood
glucose control aims to soften the abrupt increase of glucose after a
meal without risking the patient's health. This thesis will be focused
in this kind of control, which will be explained in detail in chapter 1.3.2.
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Despite all the work that has been done already, the practical realization of a
human pancreas is not yet possible, nor implanted as an articial organ due
to maintenance issues, neither emulated by an external device. The main
problem with the external approach, as stated by Hovorka [33], is the low
reliability and exactitude of the subcutaneous continuous glucose monitors,
assuming the subcutaneous (and more comfortable to the patient) interface.
Work has yet to be done in this area principally about characterizing
the monitor behavior or designing controllers that manage to overcome
measuring inexactitudes.
In addition, articial pancreas research has been developing slowly during
the last years due to ethical restrictions in the experiments, and the fact
that some health and drugs agencies only considered allowing closed loop
experiments in humans after having successful experiments with animals.
Recently, in the Diabetes Technology Meeting of 2008 [91] an Food and Drug
Administration (FDA) [24] approval was presented to substitute the stage of
experiments on animals with in silico trials with the University of Virginia
Simulator [44]. Many simulators have been developed lately for research
purposes, and most of them come from members of the Juvenile Diabetes
Research Foundation (JDRF) [40] closed-loop consortium which is one of the
most important funding entity for diabetes research in the international level.
1.3.2 Postprandial control of mixed models
Postprandial response of blood glucose is usually a sudden increase in its
concentration, usually resulting in long hyperglycemia situations, which lead
to harmful pathologies in diabetic patients. Its control and understanding is
one of the objectives of the articial pancreas project.
Modeling of glucose absorption is the most complicated issue to achieve
a good postprandial control, due to the huge variability implied in the
composition of meals, the variation between patients, and even within the
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same patient, as stated by Steil and Reifman [91]. Many models of the glucose
absorption, including dierent types of nutrients, and variable emptying rate
of the stomach have been developed in the last years, and will be shown in
the chapter 2.2.2.
The control approaches for postprandial control can be classied in three
blocks, depending on the nature of the control loop:
• Insulin delivery without meal announcement. This approach is
the pure closed loop approach, and there is no feed-forward action given
by the patient. Some variations of this approach include predictors or
alarms, that MPC controller, achieving positive results.
• Insulin delivery and qualitative meal announcement. In this
case, the patient informs the controller if there is going to be a meal
event, but there are no further specications about the event, such as
the composition of the meal or the size of it. Few work has been done
in this eld, and only one full system has been described by Panteleon
et al. [66].
• Insulin delivery and quantitative meal announcement. In this
case, there is an announcement of the meal event, and some information
about it is given, such as the amount of carbohydrates of the meal.
This situation is the most common, and is also the closest one to the
classic approach, in which the insulin bolus quantity is proportional
to the size of the meal. Many controllers have been developed for
this scenario, and tested in silico, and despite that there are some
examples of control of the postprandial glucose response in diabetic
patients, regulation to perform experiments in real patients has been
very restrictive so far, especially regulations by the FDA in the USA.
Strategies to improve postprandial response by means of an adaptive
therapy have been developed by Cesar Palerm [63] [62] as a way to
help doctors with their recommendations to patients, but no closed-
loop controllers have been developed for this case in particular.
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A dierent approach has been used by Revert et al. [81] to calculate
the best combination of basal and bolus delivery rate for the postprandial
control. This work is based on a previous one developed by Bondia et al.
[11], parting from interval analysis of dierent models. The set-inversion
methods utilized to infer the best infusion to be delivered use discretization
of glucoregulatory models under conditions of uncertainty, which permits
nding the bounding regions of all the possible glucose responses considering
some uncertainties. Calm et al. [13] already discretized postprandial models
considering uncertainty in parameters and meal intake. If only the insulin
infusion rate is considered as uncertainty, then restrictions in the blood
glucose, such as `no hypoglycemia' or `limited time hyperglycemia', describe
a set of inputs that will always accomplish with the restrictions.
The set inversion methods for postprandial control are currently being
developed by the INSULAID2 research group [12], in which this thesis
is placed. This methods, together with those developed by Palerm in
Santa Barbara, and the rest of controllers described before, have the same
requirement, and that is a model that describes the postprandial response
in detail, and that, as has been stated before, is the main problem for this




system in type 1 diabetes
One of the main problems for glucose control is the insucient accuracy
of existing mathematical models for describing the physiology of the
glucoregulatory system. In this chapter the modeling context for the articial
pancreas will be reviewed, and the state of the art of mathematical models
in literature will be described.
2.1 Behavioral and phenomenological models
It is often said that all models are wrong, but some are useful. So the
objective of a model is not to be accurate, or nd any truth, but to be useful
in the aim that it is intended to be. Walter and Pronzato [99] listed some
objectives a model may aim at. Some of them are:
• Analyzing phenomena to deepen understanding. Models for simulation.




• Controlling processes and testing controllers. Models for control.
Depending on the aim of the model (and this aim must always be clear before
starting modeling), the model is radically dierent. Models for control, for
example, tend to simplify the system they are representing much more than
models for simulation, which are usually complex, more accurate models.
A model is characterized by its structure, and this is the rst choice to
be made when deciding which model is appropriate. The main distinction
to be made when looking at the model structure is whether it has to be
phenomenological or behavioral. A phenomenological model is a model based
on prior knowledge about a physical or, in the case of the articial pancreas,
physiological principles. This kind of processes are often called knowledge-
based models as opposed to behavioral models, which merely approximate the
observed behavior of the output without any prior knowledge of the process.
Behavioral models are focused on data reproduction, and not at all in the
process behind, while phenomenological models only use the data to adjust
the parameters, while the structure is determined by the process itself.
Examples of phenomenological models are:
• Chemical reactions. Biological reactions
• Systems of force equilibrium.
• Models of deposit systems.
• Electromagnetic models. Electrical engines.





The behavioral models exposed do not have a purpose on imitating any
real process, and are all-purpose models that have to be adjusted to any
particular system, while the phenomenological models shown are specic of
the process they represent. Table 2.1 shows a comparison of the dierences
between both modeling paradigms.
Phenomenological models Behavioral models
Parameters have a concrete meaning have no concrete meaning
Simulation long and dicult quick and easy
Prior information taken into account neglected
Validity domain large (if structure is correct) restricted
Table 2.1: Phenomenological and behavioral models as seen by Walter and
Pronzato [99]
Usually, phenomenological models tend to be complex, and highly
nonlinear. Linearizing a phenomenological model changes its aim, and
therefore it changes its nature. When a nonlinear phenomenological model
is designed, its aim is usually a better understanding of the system through
simulation. Reasons for linearizing are usually attempts to control, or design
of better controllers, but this transformation neglects the prior information
of the system and its complexity, so the model results in a behavioral model,
with a restricted validity domain and lost of the meaning of the parameters.
In the context of the articial pancreas almost every model published is
phenomenological, even the simplest ones, due to the vast knowledge of the
physiology available from the physicians. There are though some methods
that use simplication and linearization of those models to extract some
information out of them, but this problem will be explained later in detail.
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2.2 Physiological processes (models) of the
glucose-insulin system
Modeling of any insulin therapy for type 1 diabetes involve three main
subprocesses:
• Insulin absorption model. This model represents the way insulin
gets into the organism, which involves its pharmacokinetics, diusion
through dierent tissues and natural insulin degradation. Insulin
absorption depends on the type of insulin used for the therapy and
the interface used for its delivery. Insulin is injected or infused in the
subcutaneous tissue, delaying its appearance in plasma compared to
insulin secretion by the pancreas. In case multiple daily injections are
used, pharmacokinetics of both rapid-acting and long-acting insulin
will have to be modeled. In case of insulin pump (and the articial
pancreas) only rapid-acting insulin is used.
• Glucose absorption model. This model is also called the
gastrointestinal model, because it involves the process of ingestion,
digestion and absorption from the intestine into blood of glucose and
other nutrients. The nutritional composition of the meal has inuence
over the process of digestion, and that may slow down the ow of
carbohydrates through the gut.
• Glucoregulatory model. The internal regulation of glucose is
represented by this model. The transformation of glycogen to glucose
by the liver (hepatic glucose production) and glucose uptake by
peripheral tissues, the inuence of dierent hormones in blood glucose,
insulin independent consumption of glucose, and in summary, every
eect that, in the organism, can aect the concentration in glucose.
The models representing all these physiological processes and relations
tend to be really complex, and it is really common to disregard some of
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the inuences on the glucose concentration, so that the model becomes
simpler and for other purposes than simulation.
The insulin absorption and gastrointestinal models are usually considered as
the input models for the glucose-insulin system, for they characterize the two
main exogenous (that come from outside the body) inputs into blood that
have inuence on the glucose concentration (gure 2.1). A good review of
the physiology and models of the systems described can be found in Amores
[3]. Other reviews in literature include Willinska review [103] and Nucci and
Cobelli review [61].
Figure 2.1: Glucose-insulin system and its subprocesses
Subcutaneous insulin injection or pump delivery is the only control
action that can be used to counteract the main disturbance considered,
meal ingestion. Insulin pharmacokinetics, has been studied for a long time,
and the behavior of insulin analogues is well documented in bibliography.
Complex glucose absorption models have been developed in the last years
with increasing accuracy, but the physiological behavior of the digestive and
intestinal absorption processes during a mixed meal ingestion, which is almost
every meal a normal person has, is yet to be represented by a gastrointestinal
model. The main diculty in characterization of the gastrointestinal model
is that absorption of glucose is only measurable with tracer methods [6],
but few studies have been done in this area so far. The only experiments
done in this area were not performed using real mixed meals, but instead
the patients ate marked jelly with eggs and bacon. The inuence of the
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nutritional composition is very relevant in the nal model output, and it has
not been taken in consideration so far.
Several models for the systems described are going to be shown in the
next sections, and later a critical review of the usefulness of these models is
going to be performed, in order to narrow down the scope of the research, not
to forget that the last objective of this thesis is identication of postprandial
models for control.
2.2.1 Insulin absorption models
Insulin absorption models are going to be reviewed starting in one
compartment model, viewing next models with several compartments and
nally to models in partial dierential equations. In order to make this
chapter easier to read, there are going to be shown only the structure and
basic concepts and equations of the model. Some models will be explained
in further detail if considered necessary.
Kobayashy et al. [43]
In this model, published in 1983, the subcutaneous absorption of a short-
acting insulin is represented by a one compartment model, with another
compartment representing the pool of insulin in blood, as seen in Figure 2.2.
The equations related to this model are:
ẋ1(t) = −kax1(t) + u(t− τ) (2.1)




The four parameters to be identied are shown in Table 2.2.
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Figure 2.2: Kobayashy model compartments
Parameter Published value Units
τ 7 min
ka 2.7× 10−2 min−1
ke 1.2× 10−2 min−1
Vd 1.5× 103 ml kg−1
Table 2.2: Nominal values of the parameters in Kobayashy's model
This was one of the rst models for insulin pharmacokinetics published,
and it was only designed for Actrapid insulin in a concentration of 40 U/ml,
which makes the model outdated (current insulin concentration are 100
U/ml).
Kraegen et al. [45]
Kraegen model was published also in 1984, and it removes the delay block
from the Kobayashy model to substitute it with a compartment that acts
as such delay. It also considers degradation of insulin in every stage of the
diusion of insulin in the interstitial space. The compartment diagram can
be seen in Figure 2.3.
The equations related to this model are:
ẋ1(t) = −(kd + k21)x1(t) + u(t) (2.3)
ẋ2(t) = k21x1(t)− (kd + kps)x2(t) (2.4)
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The ve parameters to be identied are shown in Table 2.3.
Parameter Published value Units
k21 2.97× 10−2 min−1
kd 0.0 min
−1
Kps 9.67× 10−3 min−1
Ke 9× 10−2 min−1
Vd 12× 103 ml
Table 2.3: Nominal values of the parameters in the Kraegen model
It must be pointed out that the published value of the kd parameter is
identically zero, which makes the degradation of insulin in the compartments
of insulin subcutaneous diusion non existent. This fact makes the model
identiable, while having that parameter to be identied would make the
model globally non identiable. The issue of identiability will be discussed
in depth in Chapter 3.
Puckett et al. [77]
Puckett model considered the combined action of long-acting and short-
acting insulins. Insulin degradation is only considered in the place of the
injection as an insulin eectiveness constant.
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Figure 2.4: Puckett model compartments
The equations related to this model are:




ẋ2(t) = −ka [x1(t)− x2(t)] x2(0) = 0 (2.7)
i̇(t) = kax2(t) + ke [ibh(t)− i(t)] i(0) = ib (2.8)
The dose injected is considered to have an eectiveness α, which represents
the degradation of insulin, and it is set as the initial condition of the rst
compartment x1. ib is the constant term for the plasma insulin describing the
eect of long-acting insulin, and h(t) = 1 for the rst 24 hours of simulation.
This model is non identiable, so the authors decided to agregate α and Vd
parameters in a new parameter β = Vd/α, which is shown in Table 2.4.
Parameter Published value Units
ka 1.42× 10−2 min−1
ke 6.25× 10−2 min−1
β 3.47× 10−3 ml
ib 14.58 ml
−1
Table 2.4: Nominal values of the parameters in Puckett model
Shimoda et al. [88]
Shimoda et al. published a model in 1997 valid for two subcutaneously
injected insulin preparations: soluble and monomeric insulin analogue. The
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model has the same structure for both insulin preparations, and the dierence
is only in the parameters, which are dierent for each type of insulin used.
The structure of the model is shown in Figure 2.5.
Figure 2.5: Shimoda model compartments
The equations related to this model are:
ẋ1(t) = −k21x1(t) + u(t) (2.9)





the sets of parameters for each insulin type are shown in Table 2.5.
Parameter Published value (soluble) Published value (monomeric) Units
k21 1.1× 10−2 1.7× 10−2 min−1
kps 1.5× 10−2 4.8× 10−2 min−1
kd 2.1× 10−3 2.9× 10−3 min−1
ke 9.9× 10−2 1.33× 10−1 min−1
Vd 1.25× 10−1 8× 10−2 ml kg−1
Table 2.5: Nominal values of the parameters in Shimoda model
Berger et al. [8]
Berger et al. model is a non-compartmental model that allows kinetic
description of dierent insulin preparations, such as regular, NPH, lente and
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ultralente insulins. The percent of the insulin absorbed subcutaneously with
respect to the amount injected is given by:
A%(t) = 100A(t) = 100−
100ts
T s50 + t
s
(2.12)
T50 = aD + b (2.13)
Where s, a and b are parameter depending on the insulin preparation, D
is the insulin dose, and T50 is the time interval to reach a 50% absorption
of the total dose. The insulin input ux to the plasma compartment is
easily calculated by multiplying the time derivative of A(t) by D. The single
expression for the Berger model, together with equation 2.13 stands:





Vd(T s50 + t
s)2
(2.14)
Two sets of parameters are shown in Table 2.6, one for regular insulin, and
one for NPH insulin.
Parameter Published value (soluble) Published value (NPH) Units
s 2 2 -
a 3 10.8 min U−1
b 102 294 min
ke 9× 10−1 9× 10−1 min−1
Vd 12× 10−3 12× 10−3 ml
Table 2.6: Nominal values of the parameters in Berger model
Cobelli et al. [51]
The model proposed by Cobelli's group has also two compartments for the
interstitial space, and it considers that the elimination of insulin takes place
entirely after the absorption to plasma. There are two variants of the model,
depending on the complexity considered for the model of distribution of
insulin. The rst and simpler model is the one shown in Figure 2.6.
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Figure 2.6: Cobelli model with one compartment for the plasma insulin
The absorption takes place from both stages in the subcutaneous route.
The equations related to the model are:
Ṡ1(t) = −(ka1 + kd)S1(t) + u(t) (2.15)
Ṡ2(t) = kdS1(t)− ka2S2(t) (2.16)
İp(t) = ka1S1(t) + ka2S2(t)− keIp(t) (2.17)
But the subcutaneous part is usually considered together with a more
complex distribution and elimination model, also proposed by Cobelli's
group. The new model is displayed in Figure 2.7.
Now the elimination of insulin takes places both by degradation in
the plasma compartment and in the liver, that is considered as another
compartment. The corresponding system of equations related is exactly
the same as before, but substituting equation 2.17 by the following two
dierential equations:
İl(t) = −(m1 +m3)Il(t) +m2Ip(t) (2.18)
İp(t) = −(m2 +m4)Ip(t) +m1Il(t) + ka1S1(t) + ka2S2(t) (2.19)
No published values of the parameters for T1DM people have been
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Figure 2.7: Cobelli model considering insulin in the liver and in plasma
published. Insulin pharmacokinetics parameters have not been published
either. Published values [21] for healthy and T2DM patients for the
distribution and elimination part of the model are shown in Table 2.7.
Parameter m3 is only constant for T1DM patients while for the published
cases it has dynamic behavior depending on the endogenous insulin secretion.
Nevertheless, this model is implemented in the University of Virginia
Simulator [44], and nominal parameters for healthy and diabetic patients
are used in the simulations performed with it.
Parameter Normal value T2DM value Units
m1 0.19 0.379 min
−1
m2 0.484 0.673 min
−1
m4 0.194 0.269 min
−1
Table 2.7: Published values of the Cobelli model
Willinska et al. [102]
In 2005 Willinska performed a comparison of subcutaneous models increasing
in complexity. Those models where evaluated for treatments of bolus and
continuous infusion with insulin pumps with insulin lispro, a human insulin
analog. The model with a better t to experimental data is shown in Figure
2.8.
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Figure 2.8: Willinska model compartmental structure
It is one of the most complex compartmental models existing. The
equations related to the model are:
Q̇1a(t) = ku− ka1Q1a − LDa (2.20)
Q̇1b(t) = (1− k)u−Ka2Q1b − LDb (2.21)
Q̇2(t) = ka1Q1a − ka1Q2 (2.22)














The most signicant characteristic of this model is the existence of two
channels of insulin, one of slow absorption and a fast absorption insulin
channel, both with degradation of insulin governed by a Michaelis-Menten
kinetic equation. The insulin concentration is now directly calculated from
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the fourth compartment. Published parameters of the model are shown in
Table 2.8.
Parameter Published value Units
ka1 1.12 · 10−2 min−1
ka2 2.1 · 10−2 min−1
ke 1.89 · 10−2 min−1
k 0.67 -
V 56.45 · 10−2 L kg−1
VMAX,LD 1.93 mU min
−1
kM,LD 62.6 mU
Table 2.8: Nominal values of the parameters in Willinska model
Trajanoski et al. [96]
This model considers diusion of insulin in the subcutaneous tissue and is
described by partial dierential equations. This kind of equations make this
model much more complicated than all the others, and also computationally
heavier. The Trajanoski model [96] was published in 1993 as a simplication
of Mosekilde model [57] assuming that at therapeutic concentrations insulin
binding to proteins, therefore inactive insulin, in the subcutaneous space is












−Qd3(r, t) + h(r, t)
]
+D∇2d(r, t)−Bd(r, t) (2.29)
∂i(t)
∂t







• h is the state representing the insulin concentration in subcutaneous




• d is the state representing the insulin concentration in subcutaneous
tissue in dimer state and it is measured in U
ml
.




• r is the variable representing the radial distance from the point of
injection.
• Q is the parameter representing the chemical equilibrium of the
transformation of insulin into dierent states.
• P is the parameter of velocity of the transformation of insulin into
other states.
• D is the parameter representing the diusion rate.
• B is the parameter representing the rate of absorption of insulin.
• ke is the parameter for the elimination of insulin in blood.
• Vd is the parameter for the distribution volume of insulin in blood.
In this model, a simple, single compartment model has been used for plasma
insulin dynamics, just as the Berger model. The absorption is the result of
an integral all over the control surface of the concentration of insulin in dimer
state, due to the fact that only dimer insulin is transported into blood.
Table 2.9 shows the parameters for this model.
Tarín et al. [93]
The Tarín model was developed in the same research group as this thesis.
It is a model based on the Trajanoski model and tries to extend the model
for long acting insulin glargine. This is done by considering a new virtual
compartment called bound state (not to be confound with binding state in
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Parameter Published value Units
Q 1.3× 10−1 ml2U−2
P 5× 10−1 min−1
D 9× 10−5 cm2min−1
B 1.3× 10−2 min−1
ke 9× 10−2 min−1
Vd 12× 10−3 ml
Table 2.9: Nominal values of the parameters in Trajanosky model
Trajanoski model that represents inactive insulin), which is a virtual initial
state of this type of insulin when injected. This fact adds a new partial


















= −κcb(r, t) [ch,max − ch(r, t)] + dbD∇2cb(r, t) (2.33)
∂i(t)
∂t






The variables of the model are:
• ch is the state representing the insulin concentration in subcutaneous
tissue in hexamer state and it is measured in U
ml
.
• cd is the state representing the insulin concentration in subcutaneous
tissue in dimer state and it is measured in U
ml
.
• cb is the state representing the insulin concentration in subcutaneous
tissue in bound state and it is measured in U
ml
.
And the parameters are exactly the same as for Trajanoski model, except for
the κ parameter, that represents the rate of dissociation of insulin in bound
state into hexamers, ch,max that limits the concentration of hexamer insulin
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and db that reduces the speed of diusion of the bound insulin. As for the
rest parameters, the P parameter is considered to be xed for every type of
insulin and patients, due to its low sensibility. The rest of the parameters
are shown in Table 2.10 for the Glargine insulin.
Parameter Published value (Glargine) Units
Q 3.04 ml2U−2
D 8.4× 10−5 cm2min−1
Bd 1.18× 10−2 min−1
κ 0.01 ml min−1U−1
ch,max 15 U ml
−1
db 0.1 -
ke 9× 10−2 min−1
Vd 12× 10−3 ml
Table 2.10: Nominal values of the parameters in Tarin model
An extensive identiability and identication analysis has been performed
by Ana Revert [80] in this model for lispro insulin, showing that it is able
to mimic with certain delity the behavior of dierent types of insulin,
including slow acting insulins, usually used to keep constant basal insulin
concentration.
Li-Kuang et al. [49]
Li and Kuang published a model simpler than the previous models able to
simulate dierent types of insulin. This model is based on the Tarin model,
but it does not consist of partial dierential equations, what makes it much
simpler to identify. The model adds a new equation if using slow acting
insulins such as the glargine insulin, that simulates a virtual bound state as
Tarin model does. The ordinary dierential equations that represent each
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state of insulin in Li-Kuang model are:
Ḃ(t) = −kB(t) Cmax
1 +H(t)
(2.35)
Ḣ(t) = −p(H(t)− qD3(t)) + kB(t) Cmax
1 +H(t)
(2.36)







Every equation represents a compartment, and each compartment is a state
in insulin transformation before it can go through the vascular walls in it
dimeric form. The states of the model are:
• B(t) represents the insulin in bound state. This state is only present
for slow acting insulins, and the input to the model is the initial state
of this variable in those cases.
• H(t) is the compartment representing the hexamer form of the insulin.
For regular and rapid acting insulins the initial state of this variable is
the input of the model.
• D(t) is the dimer insulin compartment.
• I(t) is the mass plasma insulin compartment. Insulin concentration
is directly calculated from this variable by dividing by the apparent
distribution volume for insulin.
In their paper of 2009 [49], Li and Kuang perform a complete mathematical
analysis of the solutions of the model, and they also propose a set
of parameters identied and extracted from bibliography. This set of
parameters is shown in Table 2.11.
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Parameter Published value (lispro) Published value (Glargine) Units
p 0.5 0.5 min−1
q 0.13 3.04 ml2U−2
r 0.2143 0.2143 -
b 0.0068 0.02 U min−1
di 0.081 0.0215 min
−1
k - 2.35× 10−5 min−1
Table 2.11: Nominal values of the parameters in Li-Kuang model
Wong et al. [108]
Wong, in 2008, published a new model for diverse insulin types with a
compartmental structure. It goes even further, predicting the behavior of
insulin kinetics when there are mixed insulin types, or multiple injections,
or mixed pump infusion. Its structure is way more complex than any other
previous, and it has a dierent compartment and dynamics for every type
of insulin considered, having dierent pools for the hexamer insulin and
dimer/monomer insulin.
The decision of use a compartmental structure for such a complex model
is based on the principle of providing a computationally-minimal model, yet
consistent, and physiologically united framework for all insulin types. The
fact of only using ordinary dierential equations speeds up the computations,
as the complexity of the structure helps with the consistency of the model.
Figure 2.9 is shown to depict the structure of the model, and for more
information, the reader is referred to Wong thesis [108] and papers [107]
[106].
The Figure shows that every insulin (NPH, Lente, RI, MI, Ultralente
and Glargine) has its own sub-model, behaves by its own kinetic, and is
one input of the main model. The model of pharmacokinetics itself is not
much dierent than the other ones that have been shown before, and in fact,
Wong uses the values of the parameters shown in previous tables as a priori
identied values, and then xes the values of those parameters in order to
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Figure 2.9: Wong model compartmental structure
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make easier the identication of each insulin block.
Summary
In Table 2.12 all the models reviewed are displayed, showing the
characteristics that make them dierent, and with which types of insulin
have been used or are capable of simulate.
Model Types of Insulin Structure
Kobayashy Actrapid 40U/ml input delay, compartmental
Kraegen - compartmental
Puckett - compartmental
Shimoda monomeric and soluble compartmental




Willinska lispro (CSII) compartmental
Trajanosky NPH and soluble PDE
Tarín glargine PDE
Li-Kuang lispro, glargine ODE no compartmental
Wong NPH, lente, RI, MI,
ultralente and glargine
compartmental
Table 2.12: Insulin absorption models. Insulin types in blank are not specied
by the authors of the model
2.2.2 Glucose absorption models
The models described in this section aim at characterizing the ux of
exogenous glucose absorbed by the intestine under dierent circumstances.
There are dierent scenarios to be simulated by these models. One of the
most common experiments performed in diabetic patients is the so called
Oral Glucose Tolerance Test (OGTT), and its objective is to observe the
response of blood glucose when the patient drinks a solution of glucose. This
glucose is rapidly absorbed by the intestine, and that boosts the blood glucose
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concentration, forcing the pancreas (if able) to secrete insulin to counteract
the rising of glucose. This scenario is broadly used to characterize sensitivity
and tolerance parameters to glucose but is of no use when compared to the
absorption of a common meal ingestion. The nature of the meal, its size and
composition, as well as the speed of ingestion, and patient conditions, have
inuence on the rate of stomach emptying [55] and the nal absorption rate of
glucose, which make the mixed meal ingestion very dicult to characterize.
The models shown in here were designed regarding to the scenarios
described, some only looking at the OGTT, others having a broader sight.
The optimal model would be able to simulate both, the OGTT and a mixed
meal ingestion, but unfortunately, there is no such thing as the perfect model.
The structure of the models for glucose absorption have some elements
in common. The gastric emptying is one of the critical points in the ow of
food through the gastrointestinal tract, due to its dependence on dierent
variables [37]. Figure 2.10 shows the general diagram for glucose absorption
models, with the food intake as input (described most of times as amount of
carbohydrates), and the exogenous ux of glucose (rate of appearance) Gex,
as output.
In the following, literature models are described.
Figure 2.10: Block diagram of the gastrointestinal model
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Hunt et al. [38][94]
The model presented here is an extended version of the Hunt model. Hunt
et al published a model of gastric emptying in 1975 extended in its intestinal
absorption part by Teufel. The combined system is a very complete model
that uses a set of algebraic equations to characterize the gastric emptying,
and a set of partial dierential equations to simulate the transformation of the
carbohydrates from their polysaccharide form into the nal monosaccharide
form, which is the only one that is possible to be absorbed by the intestine
walls.
The equations related to the gastric emptying are not ordinary dierential
equations, but algebraic, and the output is not the ux of glucose due to the
gastric emptying, but the volume of glucose remaining in the stomach V (t).
V (t) = V0e










(0.0167mch + 0.0167mprot + 0.0377mlip) (2.41)
The solution to the previous equations will give the remaining volume of
carbohydrates in the stomach. Operating with that variable, the output of
the stomach as a ux of carbohydrates can be obtained. The parameters and
variables involved are:
• V is the stomach volume, measured in ml. V0 is the value of the variable
at time 0.
• Vmeal is the total volume of the ingested meal.
• a represents the emptying speed of the stomach.
• κ is the weighted inuence of the amount of carbohydrates, lipids and
proteins in the gastric emptying.
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• mch is the total amount of carbohydrates present in the meal in mg.
• mprot is the total amount of proteins present in the meal in mg.
• mlip is the total amount of lipids present in the meal in mg.
Once determined the rate of emptying of the stomach, the rest of the
model consists in a series of partial dierential equations for every stage




p(z, t) = −υ ∂
∂z
p(z, t)− Qpp(z, t)








Kmp + p(z, t)
− Qoo(z, t)

















The gastric emptying will come into the previous equations as a boundary
condition in p(0, t), and then carbohydrates will move forward in the linear
space z that represents the gut space. The transformation uxes are dened
by a Michaelis-Menten dinamic equation, and the exogenous ux of glucose is
calculated considering the monosaccharides present in all the intestine. Each
Michaelis-Menten equation adds two new parameters that will have to be
identied. The published values of these parameters are shown in Table 2.13
with the rest of the published parameter values.
Hovorka et al. [34]
Hovorka proposed a much simpler model for glucose absorption in his paper of
2004, where the gastrointestinal system is modeled by compartmental model
with two identical compartments with the same transfer rate. Later, the
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Parameter Published value Units









Table 2.13: Nominal values of the parameters in Hunt model
model was rened in a new paper [101] considering the transfer rate tmax as
















• D(t) is the amount of carbohydrates ingested in grams. The meal in
this model is considered as a pulse input.
• Bio is the eectiveness of the absorption of the carbohydrates ingested
i.e. is the portion of the carbohydrates that have been eaten that will
go into the circulatory system.
• tmax is the maximum absorption time of the carbohydrates. This
parameter regulates the transfer speed between the compartments. It
is a bounded parameter following:
tmax =
{




where tmax ceil =
G2
Gex ceil
and Gex ceil is the maximum glucose ux from
the gut.
The nominal values of the parameters are shown in Table 2.14.
Parameter Published value Units
tmax 40 min
Bio 0.8 -
Gex ceil [0.02, 0.035] mmol kg
−1 min−1
Table 2.14: Nominal values of the parameters in Hovorka model
This model has the weakness of not considering the dierent compositions
of mixed meals, as most models. That is not the aim of this model though,
but to rapidly provide a coherent input for the glucoregulatory system.
Fabietti et al. [23]
Fabietti et al. published a model of the complete glucoregulatory system,
with a gastrointestinal part, that is going to be described in the following
lines. The model considers three paths of absorbing nutrients, depending
on the nature of the meal ingested. The speed of absorption is related to
the complexity of the carbohydrates present in the meal. For example, if
the meal has a high percentage of glucose in its monosaccharide form, the
absorption will be done mainly through the fastest path, and making it slower
as the complexity of the carbohydrates increases in the meal (majority of
polysaccharides).
The type of input is also dierent depending on whether we consider the
meal as an impulse or a pulse signal (Figures 2.11 and 2.12 respectively).
Once determined the shape of the input the meal is decomposed into
monosaccharides and fast/slow absorption polysaccharides, with dierent
dynamics, following the hierarchy shown in Figure 2.13. The parameters
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Figure 2.11: An impulse meal input. All the meal is considered to be eaten
instantaneously
Figure 2.12: A pulse meal input, considered along a period of time
Figure 2.13: The meal is absorbed by a dierent model in the proportions
marked by Fs and Fm
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Fs and Fm are parameters dependent on the composition of the meal being
ingested. The equations that follow are each one of the models for the
channels of absorption. Note that the order of the system decreases with
the speed of absorption of the carbohydrates:




As(s) = Fs(1− Fm)
467




(s+ 0.466)(s+ 5.54)(s+ 5.86)(s+ 6.43)
Ri(s) (2.52)
Gex = Ag + As + Am (2.53)





· (1 − e−εs) for a pulse
meal of duration ε.
This is a very sti model, and its structure only changes with the shape of
the input considered and with the composition of the meal. The parameters
related to the poles and zeros of the models for every kind of carbohydrates
are already given.
Natalucci et al. [60]
The Natalucci model is a very simple set of two equations, in which one
describes the evolution of the amount of glucose in the gut, while the other
represents the gastric emptying rate. These equations are:
Rge(t) = Dkβe
(−kt)β (2.54)
Ġgut(t) = Rge(t)− kabsGgut(t) (2.55)
where D is the amount of glucose ingested in mg. Once solved the equations
shown above, the rate of appearance is easily calculated by:
Gex(t) = kabsGgut(t) (2.56)
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This model only considers the absorption of glucose in a OGTT scenario,
and it is of no use when trying to simulate a mixed meal. The parameters
identied by Natalucci are shown in Table 2.15.





Table 2.15: Nominal values of the parameters in Natalucci model
Elasho et al. [32]
The model proposed by Elasho et al. is quite similar to the proposed by
Natalucci, but with a more complex formula for the gastric emptying, and a
new parameter f that denes the eectiveness of the absorption of glucose by
the gut. The rate of gastric emptying is going to be denoted here as Gempt(t)






Ġgut(t) = Gempt(t)− kabsGgut(t) (2.58)
Gex(t) = fkabsGgut(t) (2.59)
And the published parameters related are those in Table 2.16.






Table 2.16: Nominal values of the parameters in Elasho model
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Lehmann et al. [48]
Lehmann model denes the gastric emptying as a trapezoidal function





· t if t < Tup
Vmax if Tup ≤ t < Tup + Tmax
Vmax − VmaxTdown · (t− Tup − Tmax) if Tup + Tmax ≤ t < Tup + Tmax + Tdown
0 otherwise
(2.60)
Figure 2.14: The form of the gastric emptying is a trapezoidal function
where parameters characterize the nature and composition of the meal,
as well as the patient behavior in front of that particular meal. Vmax can be
directly calculated by considering that the area of the trapezoid is the total
amount of glucose ingested (D), as follows:
Vmax =
2D
Tup + 2Tmax + Tdown
(2.61)
The rest of the parameter values published are shown in Table 2.17.
The intestinal absorption part of the model is dened a a single-
compartment model as in the previous models exposed. The equations
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Table 2.17: Nominal values of the parameters in Lehmann model
related are:
Ġgut(t) = Gempt(t)− kabsGgut(t) (2.62)
Gex(t) = fkabsGgut(t) (2.63)
Dalla Man et al. [20]
Chiara Dalla Man published in 2006 a complete gastrointestinal model and
a critical review of the existing models in literature. This model considers
a two-compartment model for digestion and a simple single-compartmental
model for the absorption in the gut. The model follows the structure shown
in Figure 2.15.
The two compartments in the stomach part suppose two parts of the
digestion of glucose before the gastric emptying. The emptying of the
stomach is a non-linear function of the total amount of glucose in the stomach,
as will be shown in the model equations later. The compartmental model
equations are:
q̇sto1(t) = −K21qsto1(t) +Dδ(t) (2.64)
q̇sto2(t) = −Kempt(qsto)qsto2(t) +K21qsto1(t) (2.65)
q̇gut(t) = −Kabsqgut(t) +Kempt(qsto)qsto2(t) (2.66)
Gex(t) = fKabsGgut(t) (2.67)
where δ(t) is the Dirach delta, simulating an impulse input to the model.
The rest of parameters added are ux constants, for the transfer of glucose
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Figure 2.15: A two compartment model represents the stomach and a single
compartment the intestine
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through the system, except for the Kempt parameter, which is time-varying
and denes the form of the gastric emptying. The equations describing the
transfer rate describing the ow of glucose from the stomach to the intestine
are:




·{tanh[α(qsto − b ·D)]− tanh[β(qsto − c ·D)] + 2}
(2.68)








These equations give the gastric emptying a very characteristic shape. In
Figure 2.16 the Kempt is plotted against the amount of glucose remaining in
the stomach qsto.
The parameters have been identied both for an Oral Glucose Tolerance
Test (OGTT) and a mixed meal. Parameter K21 is forced to be equal to
Kmax for identiability issues. The published values are shown in Table 2.18.
Parameter Published value (OGTT) Published value (meal) Units
Kabs 0.205 0.071 min
−1
K21 0.045 0.054 min
−1
Kmax 0.045 0.054 min
−1
Kmin 0.013 0.006 min
−1
b 0.85 0.69 -
c 0.25 0.17 -
Table 2.18: Nominal values of the parameters in Dalla Man model
Some work has been done within this research group on identiability
of mixed meals with the Dalla Man model [5], showing a dependence of
the identication results on the size of the meal considered. A library of
identied meals has also been developed by Pau Herrero in 2008 [31]. Dalla
Man model will be also studied in this thesis and used to design optimal
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In Table 2.19 all the gastrointestinal models reviewed are displayed, showing
their structures for the stomach and intestine parts, and the gastric emptying
process.
Model Stomach Intestine Gastric emptying
Hunt algebraic PDE direct
Hovorka - 2 compartments -
Fabietti - 3 transfer functions -
Natalucci 1 compartment 1 compartment algebraic
Elasho 1 compartment 1 compartment algebraic
Lehman - 1 compartment trapezoidal
Dalla Man 2 compartments 1 compartment depends on mass of
CHO in the stomach
Table 2.19: Glucose absorption models
2.2.3 Endogenous models
Glucoregulatory models for type 1 diabetic patients are going to be described
in the following lines. The endogenous model is the part of the glucose-
insulin model that describes the dierent regulatory pathways of blood
glucose concentration. Given that this thesis is focusing in the control and
identication of T1DM people, the authors decided that the dynamics and
equations describing the secretion of insulin were no relevant to be shown for
those models that describe it.
Usually the endogenous model has two sub-models, one for the insulin
distribution and elimination system (if not considered in the insulin
absorption model), and the other for the glucose metabolism, transformation
and elimination. This second sub-model has to consider the inuence of the
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liver and the kidneys on the blood glucose, as well as the peripheral intake by
muscles and adipose tissue, and any other inuences that may aect glucose
concentration. The complexity of the model will be increasing as more eects
are considered in the modeling of the metabolic phenomena present in this
system.
Bergman et al. [9]
The rst model to be reviewed is going to be the (probably) most used and
best known among all the models used in diabetes. It is called the Bergman
minimal model because it only describes the inuence of insulin on blood
glucose concentration, and it does not consider many other phenomena, or it
considers them in a very simplied way. The justication for this simplicity
is that the objective of this model was, initially, to simulate the response of
the IntraVenous Glucose Tolerance Test (IVGTT), which has a very simple
behavior.
Bergman minimal model considers that insulin actions on glucose are
delayed, and that delay is represented by a new compartment of remote
insulin. The scheme of the model is shown in Figure 2.17.
The equations related to the model are:




Ẋ(t) = −p2X(t) + p3[I(t)− Ib] X(0) = 0 (2.72)
Ġ(t) = −p1G(t)−X(t)G(t) + p1Gb +
u2(t)
V olgG
G(0) = Gb (2.73)
Depending on the model of insulin absorption used, equation 2.71 can be
substituted by the corresponding equation of the model chosen. X(t) is the
remote insulin compartment, G(t) is the blood glucose concentration, u1(t) is
the insulin ow coming from the insulin system, u2(t) is the exogenous ow
of glucose coming either intravenously or from the gastrointestinal system.
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Figure 2.17: Bergman minimal model of insulin and glucose dynamics,
adapted from Bergman and colleagues [9]
Published values for the model parameters are shown in Table 2.20.









V olG 117 dl
Table 2.20: Nominal values of the parameters in Bergman model [85]
Bergman model has been used for more than 20 years in diabetes research
due to its identiability and controllability properties, but it is far of being
the perfect model. There have been many critics to this model, both from
the medical and control point of view [79], and later on this thesis, Bergman
model will be analyzed in detail. In fact, this is one of the models tested and
used for experimental design in this work.
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Panunzi et al. [67]
Simona Panunzi and the group of biomathematics in Rome published a study
in 2007 comparing some of the characteristics of Bergman model and new
features of a proposed model for the IVGTT scenario, with a delayed insulin
secretion rate. The new model proposed surpassed the rest in simulated
experiments and in identiability properties, but it was only tested in healthy
patients. The equations of the model are:
















This model includes delayed dierential equations for the insulin production
sub-model, but when simulating type 1 diabetic patients, whom do not have
endogenous insulin secretion, the model becomes much more simple. The
parameters involved in the previous model are:
• Gb is the basal glucose concentration.
• Ib is the basal plasma insulin.
• Kxgl is the insulin sensitivity. It represents the insulin-dependent
glucose uptake by tissues per unit of insulin concentration.
• Tgh represents the balance between the hepatic outtake of glucose and
the insulin-independent glucose intake, including the one of the liver.
• Vg is the apparent glucose distribution volume.
• Kxi is the disappearance rate of insulin.
• G∗ is the glycemia at which the insulin secretion rate is half of its
maximum.
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• Tig max is the maximum rate of insulin release.
• Vi is the apparent insulin distribution volume.
• τg represents the apparent delay with which the pancreas changes
insulin release in response to a variation in blood glucose.
• γ is the progressivity with which the pancreas reacts to circulating
glucose concentrations.
The values published for these parameters, only for healthy patients, are
shown in Table 2.21.
Parameter Published value Units
Vg 0.152 L kg
−1
τg 19.271 min




Table 2.21: Nominal values of the parameters in Panunzi model
Panunzi model is also considered for the study performed in this thesis
because of its simplicity, but some variations were made due to the focus of
this model on healthy patients and the IVGTT scenario.
Vicini et al. [98]
Vicini et al. published a simulation (non-minimal) model in 1999. The
compartmental structure of the model for a healthy person is shown in Figure
2.18.
The model for diabetic patients is slightly dierent than the one shown
for healthy patients. A type 1 diabetic patient will not have insulin secretion
S(t) and so, compartment q4(t) disappears, and every insulin input will go
directly from the subcutaneous insulin model, into the q3(t) compartment,
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Figure 2.18: Vicini model compartmental structure for a healthy person. It
consists of two compartments for glucose, two for insulin and two virtual
insulin actions [98]
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which is the plasma insulin compartment. The variables related to the model
are:
• q1(t) is the compartment representing the blood glucose mass.
• q2(t) represents the mass of glucose in the interstitial uid.
• q3(t) is the plasma insulin mass compartment.
• xr(t) is the remote insulin action on the glucose production.
• xu(t) is the remote insulin action on glucose utilization.
• Di is the insulin input. In this model, insulin is considered to be an
intravenous bolus (impulse).
• D is the glucose input. In Figure 2.18 it is considered as an intravenous
impulse input, but again, if instead of the Dirach delta δ(t) there is a
digestive model, the input is the output of the gastrointestinal model.
• P (t) Is the endogenous glucose production.
The equations of the model are:
q̇1(t) = −[kp +
Rd,0
q1(t)
+ k21]q1(t) + k12q2(t) + P (t) +Dδ(t) (2.76)
q̇2(t) = −[k02 + k12 + xu(t)]q2(t) + k21q1(t) (2.77)
q̇3(t) = −k03q3(t) +DIδ(t) (2.78)
ẋu(t) = −kaxu(t) + ku[I(t)− Ib] (2.79)
ẋr(t) = −kaxr(t) + kr[I(t)− Ib] (2.80)










Finally, the parameter values published by the authors are shown in Table
2.22.
Parameter Published value Units
V1 1.58 dl kg
−1
















ku 6.48× 10−6 µIU ml−1 min−2
kr 3.76× 10−5 µIU ml−1 min−2
Rd,0 1 -
Pb 4 mg kg
−1 min−1
Table 2.22: Nominal values of the parameters in Vicini model
Cobelli et al. [21]
Cobelli model is one of the most important models in diabetes research. It
is a very complex model almost exclusively based in physiological knowledge
of the glucose metabolism. It is usually combined with the Dalla Man
gastrointestinal model and the insulin pharmacokinetics model of the same
group (in fact all the models were developed together) in a large mathematical
model of the glucose metabolism. Magni et al. [51] used the complete
Cobelli model to control an in silico diabetic patient. It is also the model
implemented in the UVa (University of Virginia) simulator [44], accepted by
the FDA as substitute of animal trials in the context of a protocol application
of University of Virginia and Padova for a controller validation clinical trial.
The core structure is pretty simple, as shown in Figure 2.19:
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Figure 2.19: Cobelli model core is composed of two compartments of glucose,
one for blood and one for the tissues interstitial uid
The model equations are:
Ġp(t) = EGP (t) +Ra(t)− Uii(t)− E(t)− k1Gp(t) + k2Gt(t) (2.84)
Ġt(t) = −Uid(t) + k1Gp(t)− k2Gt(t) (2.85)
G(t) = Gp(t)/VG (2.86)
In the previous equations there are many inputs and outputs to the glucose
compartments that have to be described. It must be noted that so far there
is no insulin related equations; insulin will have inuence in the ow of
glucose coming in or out of the dierent compartments. The meaning of
these variables will be explained now:
• Ra is the exogenous ux of glucose coming from the gut.
• Uii is the utilization of glucose that is non dependent on insulin. It is
usually considered constant and equal to Fcns.
• Uid is the utilization that depends on the insulin concentration, and it
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follows the following set of equations:
Ẋ(t) = −p2UX(t) + p2U [I(t)− Ib] (2.87)





where X(t) is the remote insulin, I(t) is the plasma insulin, Ib is the
basal insulin and Vm(t) is the transfer rate for the Michaelis-Menten
equation shown in equation 2.89.
• E(t) represents the renal excretion, which occurs if plasma glucose
exceeds a certain threshold. Is modeled as follows:
E(t) =
{
ke1[Gp(t)− ke2] if Gp(t) > ke2
0 otherwise
(2.90)
where ke1 is the glomerular ltration rate and ke2 is the renal threshold
of glucose.
• EGP (t) is the Endogenous Glucose Production, and it depends on a
delayed insulin signal as follows:
İ1(t) = −ki[I1(t)− I(t)] (2.91)
İd(t) = −ki[Id(t)− I1(t)] (2.92)
EGP (t) = max{0, kp1 − kp2Gp(t)− kp3Id(t)} (2.93)
where I(t) is the insulin concentration in plasma.
The published parameters for healthy and type 2 diabetic (no type 1 diabetic
parameters have been published) patients are those in Table 2.23. Even
though the parameters shown are those of a healthy and T2DM patients, no
endogenous production of glucose has been described in here fot this model,
which is the case of a T1DM person.
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Parameter Healthy Type 2 diabetes Units
VG 1.88 1.49 dL kg
−1
k1 0.065 0.042 min
−1
k2 0.079 0.071 min
−1
kp1 2.70 3.09 mg kg
−1 min−1
kp2 0.0021 0.0007 min
−1
kp3 0.009 0.005 mg kg
−1 min−1 per pmol L−1
ki 0.0079 0.0066 min
−1
Fcns 1 1 mg kg
−1 min−1
Vm0 2.5 4.65 mg kg
−1 min−1
Vmx 0.047 0.034 mg kg
−1 min−1 per pmol L−1
Km0 225.59 466.21 mg kg
−1
p2U 0.0331 0.0840 min
−1
ke1 0.0005 0.0007 min
−1
ke2 339 269 mg kg
−1
Table 2.23: Nominal values of the parameters in Cobelli model
Hovorka et al. [36]
Roman Hovorka endogenous model regards separately at each action of
insulin on dierent phenomena with its nal eect on blood glucose. The
model adds a new compartment for every action of insulin, and there are
three considered events:
• Insulin increases the ow of glucose from blood to the tissues.
• Insulin increases the glucose uptake by muscles and adipose tissue.
• Insulin inhibits production of glucose of glucose in the liver.
These three inuences are reected in the model as virtual compartments.
The relation between actual insulin in plasma, every virtual compartment
representing insulin actions and the two compartments for glucose is shown
in Figure 2.20. x1, x2 and x3 represent the insulin actions, Q1 is the glucose
mass in the accessible compartment, and Q2 is the glucose present in the
non-accessible compartment.
76
Figure 2.20: Hovorka endogenous model structure arranged in compartments
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The equations that represent this model are:
ẋ1(t) = −ka1x1(t) + kb1I(t) x1(0) = 0 (2.94)
ẋ2(t) = −ka2x2(t) + kb2I(t) x2(0) = 0 (2.95)







Q1(t) + k12Q2(t)− FR + EGP +Gex(t) Q1(0) = Q1,0
(2.97)
Q̇2(t) = x1(t)Q1(t)− [k12 + x2(t)]Q2(t) Q2(0) = Q2,0 (2.98)
G(t) = Q1(t)/VG (2.99)
Equation 2.97 has several terms that have to be dened:
• EGP stands for Endogenous Glucose Production, which is the ux of
glucose coming from the liver. It is dened as:
EGP =
{
EGP0[1 + x3(t)] if EGP ≥ 0
0 otherwise
(2.100)








• FR is the renal glucose clearance above the glucose threshold of R_thr,
and it is dened as:
FR =
{
R_cl(G−R_thr)VG if G ≥ R_thr
0 otherwise
(2.102)
Where R_cl is the renal clearance.
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The model has many parameters to be identied, specially in the part of
insulin actions, where there are two parameters for each action corresponding
to the input and output ows of the compartment. Usually these parameters
are reformulated into what are called insulin sensitivities, due to their
physiological meaning since they correspond to the glucose decrement per
unit of insulin given. The reformulation is then:
• SIT = kb1ka1 where SIT is the insulin sensitivity to the transport of glucose.
• SID = kb2ka2 where SID is the insulin sensitivity to the distribution of
glucose.
• SIE = kb3ka3 where SIE is the insulin sensitivity to the endogenous glucose
production.
After this transformation, equations (2.94), (2.95) and (2.96) result in:
ẋ1(t) = −ka1x1(t) + SITka1I(t) x1(0) = 0 (2.103)
ẋ2(t) = −ka2x2(t) + SIDka2I(t) x2(0) = 0 (2.104)
ẋ3(t) = −ka3x3(t) + SIEka3I(t) x3(0) = 0 (2.105)
The published values of all the parameters are those in Table 2.24. The
parameters shown in here are mean values of the several sets of parameters
published.
Hovorka model hss been used both for simulation and control purposes, in
many dierent scenarios, from critical patients [35] to overnight experiments
[34] with successful results, and recently it has been implemented in a
complete mathematical patients simulator [101], like the UVa simulator.
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Parameter Published value Units
k12 0.066 min
−1
VG 0.16 L kg
−1
EGP0 0.0161 mmol kg
−1 min−1












SIT 51.2× 10−4 mU L−1 min−1
SID 8.2× 10−4 mU L−1 min−1
SIE 520× 10−4 mU L−1 min−1
Table 2.24: Nominal values of the parameters in Hovorka model
Summary
In Table 2.25 all the gastrointestinal models reviewed are displayed, showing
their structures for the stomach and intestine parts, and the gastric emptying
process.
Model Purpose Implemented in
Bergman control (minimal) -
Panunzi control (minimal) -
Vicini simulation -
Cobelli simulation UVa simulator
Hovorka simulation Hovorka simulator





The identication of the parameters of a model is an inverse problem. An
inverse problem consists in nding the conditions and inputs to a system
given the outputs of the system. In the glucose-insulin model identication,
the inverse problem is to nd parameters and model that characterize a
patient given the glucose behavior of that patient.
Identication can be solved by means of optimization algorithms that try
to optimize an index of the t of the model's output to the available data.
That index can be formulated, for example, as a quadratic error depending




(yi(p)− ỹi)TQi(yi(p)− ỹi) (3.1)
where yi(p) are the model predictions and ỹi are the experimental
measurements, therefore, the data that has to be tted. Qi is the data
weighting matrix, which permits to t more accurately some data in
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detriment to other data samples. Qi is usually chosen as a diagonal matrix,
due to the assumption that data samples are independently correlated to each
other. The choice of the diagonal values in the matrix are usually referred
to as weights of the data samples.
A usual compromise choice for the ponderation matrix is to make the
relative errors of each data sample weight the same in the cost index. This is
achieved by forcing the diagonal of Qi to be equal to 1/ỹ
2
i . This ponderation
matrix has the disadvantage of giving less importance to big errors in big
values of the output of the model than in small values. Usually it is desired
that all errors are normalized in the optimization index, and this is achieved
with other Qi, like for example all the elements of the diagonal to be equal to
1/max(ỹi)
2. This way the contribution of every data sample is standardized
and the errors are not weighted in any way.
Countless strategies and softwares have been developed for every specic
type of optimization problem. There are several methods focused in
parametric identication and a couple of them will be explained in the last
part of the chapter.
In order to analyze the structural properties of the model, it is necessary
some kind of study to try to forecast if the problem is going to be solvable
and in which terms. This is what is called identiability study.
3.1 Identiability a priori
Considering now the case of a given model and given parameters, the
identiability of the system can be studied at two dierent levels. By one
side, there is the identiability of the parameters given the structure and
under ideal conditions, and by the other side there is the identiability of
the parameters given the parameter values, and considering measurement
noise. The rst case is called identiability a priori and the second is the
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identiability a posteriori.
There are many methods for testing models for structural identiability
and the one that will be shown next is completely valid for non-linear models.
That method is the Taylor series approach for identiability a priori.
Taylor series approach
Considering then an state-space, non-linear, time invariant model:
d
dt
X(t) = f [X(t), u(t), t, P ] x(0) = x0(p) (3.2)
y(t, P ) = h[X(t), P ] (3.3)
here X(t) is the state vector, y(t, P ) is the output of the model, u(t) is
the input, P is the vector of parameters, and f(·) and h(·) are non-linear
functions. In this case, dening the derivative order k of the output as:




y(t, P ) (3.4)
then, based on Pohjanpalo's paper [75], if ak(P̂ ) = ak(P
∗) yields P̂ =
P ∗, then the model is structurally identiable, which means that only one
set of parameters can simulate a determined output. Notation has been
chosen to be coherent with [99], and P̂ represents the model parameters,
while P ∗ represents the system's hypothetical real parameters. Examples,
further explanations and more methods can be found in [99] and [82].
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3.2 Identiability a posteriori
Now, the fact that a model is structurally identiable does not mean that
identications performed to that model are going to be successful. There
is another type of identiability that has to be tested that will determine
if a given set of parameters can be estimated from the outputs they give.
Obviously, if there is no a priori identiability, i.e. there is more than one
set of parameters that can produce the same output, it will be impossible
to identify the model. But the information contained by a realization of the
model may be insucient to induce which parameters produced it, and that
information analysis is what a posteriori identiability consists in.
Again, there are several methods to quantify the identiability of a model,
but only one will be shown in detail in the following, the Fisher Information
Matrix (FIM) approach.
The Fisher information matrix approach
Analyzing with detail the Fisher Information Matrix (FIM from now on), all
information about identiability of the model can be extracted, but only in
local basis, due to the fact that this method's application implies linearization
of the model.
To understand the method, let's take the index dened in equation 3.1.
The statistical estimation of the index for a set of parameters slightly dierent
of the optimal is given by:


















where Vi represents the covariance matrix of the measurement errors (Qi
is typically chosen as V −1i ), z is the model output and N is the number of
data samples. The term between brackets is what is known as the Fisher
Information Matrix and it expresses the quantity of information contained
















The terms ∂z/∂p are the sensitivity functions and they are of great
importance for the evaluation of the practical identiability. The FIM is
a square matrix with dimension equal to the number of parameters that are
to be identied. The inverse of the FIM is also an approximation of the
covariance matrix of the estimation error of the model parameters:














The diagonal of C contains the information of the condence interval
in the estimation of every parameter. The maximum lower bound of this
condence interval is called Cramer-Rao Bound. Cramer-Rao also dened
the inverse of the FIM evaluated in the real parameters as the lower bound
of the covariance matrix of the parameters (in the real system). The bound of







The interpretation of the Cramer-Rao limit is simple. If, for example,
a parameter pi has a CV of 0.4 it means that, for the measurement error
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which variance was considered in the calculation of Qi, successive parameter
estimations will have a deviance of 40% of the parameter value. As such,
coecient of variation is a relative measure of the parameter standard
deviation given the error variance considered in Qi = V
−1
i , being Vi the
the error variance. There is more useful information to be drawn o the
FIM, like the correlation matrix. This matrix, the elements of which are
the approximated coecients of correlation between the ith and the jth





Analyzing the correlation matrix gives and idea of the compensation eect
of the changes in the values of the parameters over the model output. If two
parameters, pi and pj, are highly correlated, a change in the output due to a
change in parameter pi can be hidden by the appropriate change in pj.
In practical terms, the identiability analysis must be done applying some
simplications. The sensitivities of the parameters have to be calculated by
approximating the derivatives of the output with rst order approximations.
In general, application of the analytic expression of the derivative function is
the correct way of performing the FIM calculation. With the models exposed
before though, the analytical expression of the derivative with respect to the
parameters of the outputs of those equations is not feasible, and it has not
been done in here.
Usually, the sensitivity function is calculated applying the linearization of
the model around the nominal parameter, and obtaining the symmetric rst
order dierence. In practice, two simulations of the model are calculated,
one with a positive variation of the selected parameter, and the other with a
negative variation, as seen in Figure 3.1. The sensitivity function is calculated
with equation (3.10).
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Figure 3.1: A three meals simulation with perturbation in one parameter is
shown. The blue line represents the nominal parameter's simulation, while





Also, if the FIM results to be singular it can not be inverted, and that is
a sign of non-identiability. In fact, it is a sign of a priori non-identiability,
so that analysis is being carried out with this method as well. Usually,
when working with noisy measurements, it is really dicult to get that
the FIM is completely singular, and yet it will be dicult to identify any
parameter because the FIM is bad-conditioned. The condition number has
to be analyzed then, and checked if it is large enough to permit inversion of
the matrix and identiability.
When ill-conditioning happens the solution is usually to x some
parameter to a determined value. The decision of which parameter to x
is taken from the singular value decomposition analysis of the sensitivity
matrix. Dening the sensitivity matrix as a matrix with as many columns
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as parameters being analyzed, and rows as data samples, decomposition can
be applied and interesting properties arise. Singular Value Decomposition
(SVD) is dened as:
M = UΣV ∗ (3.11)
where M is the matrix being decomposed in three other matrices. Matrix U
is a unitary square matrix, Σ is a diagonal matrix with non-negative values
of the same dimensions as M , and V ∗ is the conjugate transpose of V , which
is another unitary square matrix. For further information about the singular
value decomposition check the classic reference of Golub [28].
Applying that decomposition, the values of the diagonal matrix Σ
quantify the sensitivities of the singular directions in the parameter space
in decreasing order. The last value of the diagonal is then the less
sensitive direction of the parameter space. In order to nd what parameter
has the bigger inuence in that direction (and then, which is the less
inuential parameter), one have to look at the V matrix of the singular value
decomposition. The columns of V are the eigenvectors of the sensitivity
matrix and the last column expresses the inuence of the parameters in the
less sensitive direction of the parameter space. The bigger entry in the last
eigenvector denes the parameter to be xed in the identiability analysis.
In summary, there are two ways of increasing the identiability of a model:
(1) Changing the experiment paradigm. (2) Not to try to identify some of
the parameters, the decisions of which parameter to x being taken based on
the identiability analysis results, for example, depending on the sensitivity
matrix properties or with the correlations between parameters.
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3.3 Practical Identiability
So far theoretical background on identiability analysis has been explained
and some broadly used methods for the calculation of identiability
estimators has been given. In the following lines there is a depiction of
the steps taken to quantify identiability in this thesis, as well as some hints
for calculation of the FIM and its estimators.
Given a model and a set of parameters, the sensibility analysis has to
be performed at rst. Variations on the number of parameters will have to
be done until there is a model found identiable, but identiability has to
be quantied. In the case of this thesis, a model is identiable when all the
parameters of the model analyzed have coecients of variation of less than 0.3
and there are no correlations between the parameters greater than 0.98. For
non-invertible matrices, the singular value decomposition explained in the
previous section can be carried out in order to determine which parameter
to x. The steps to follow in order to determine which set of parameters are
identiable can be seen in Figure 3.2.
Figure 3.2: The model starts with all of its parameters, but they fall o
the identication as prove themselves not sensible enough or too related to
another parameter
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Following that ow chart, the sensitivity analysis starts with all the
parameters of the model i.e. `p' parameters. The sensitivities of all the
parameters are calculated, and the FIM is evaluated. If the FIM is singular,
it means that it is not invertible, and thus, no condence intervals for the
estimation of parameters are calculable. Non-invertibility is always related to
a small condition number of the matrix, and that is why the most ecient way
to estimate the invertibility of the matrix is calculate its condition number.
A condition number of 10 times the maximum oat precision, i.e. 2.2 · 10−16
is considered small enough to label the matrix as non-invertible [82]. When
this happens, the most inuent parameter in the smallest singular value's
eigenvector is xed to it's nominal value, and it is not used anymore in
sensitivity analysis. The analysis considers now `p-1' parameters, and the
FIM is now a matrix of dimensions (p-1)×(p-1).
Once the FIM has an inverse matrix, the objective of the analysis is to
reduce coecients of variation (CVs) of the rest of the parameters. The
Cramer-Rao bound has to be calculated for every parameter, and the one
with the highest value is then xed, reducing the number of parameters of
the analysis by one. After several iterations, when all the parameter CVs
are to be under a prexed value, let's say under 0.3 (as it says in Figure
3.2). A value of 0.3 will guarantee that at least the sign of the value will be
captured. The decision of which parameter to x in this case is up to the
user. Of the two parameter correlated, one has to be xed, and it can be
either the one with the highest CV, or the one that is lower in the inuence
ranking (that may dier of the highest CV parameter due to the correlations
not considered in the ranking).
Once the appropriate set of parameters is selected, there is still the
question of whether or not the model is truly identiable. Identiability
has been calculated and it has resulted theoretically satisfactory, but many
simplications and assumptions were made in the way, so a real attempt of
identication may not be successful. In other words, the sensitivity analysis
has to be validated. In order to do so a virtual identication can be performed.
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Virtual identication is an identication in which the experimental data
is obtained from simulation, and error is added to the signal, so it emulates
possible measurement or modeling errors in the real identication. With the
noise addition trick multiple data sets can be obtained, and so statistics of
the identication, referring to every data set as a sample, can be calculated.
These statistics can be comparable to the outputs of the sensibility analysis,
being then able to validate it's success or to disprove it. The ow chart
summarizing the steps to perform a virtual identication can be seen in
Figure 3.3.
Figure 3.3: The nal objective of the virtual identication is to nd similar
results as the sensitivity analysis, under the same conditions
Following the ow chart, we start from a set of known parameters
(nominal parameters), and the sensitivity analysis has already been
performed. The model simulation is performed, obtaining perfect data,
without noise or variation in the parameters. By adding dierent realizations
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of a white noise (mean 0 and uncorrelated), several noisy data, that can
be considered as dierent outputs of the model, are obtained. Identication
is then carried out to all of the noisy sets of data, obtaining multiple sets
of parameters identied. Statistics can be calculated for every parameter,
because from the dierent identications the same parameter has been
identied many times. The mean values of every parameter has to be
comparable to the initial (nominal) parameter. The deviations of the
identications for each parameter must be contained in the condence
intervals obtained by the sensitivity analysis, following the same probability
distribution.
If sensibility analysis and virtual identication statistics are (roughly)
similar, then the model is proven to be identiable, as long as the nominal
parameters considered are correct. This does not mean that the model is
correct. The aim of identication is to nd a model that imitates the behavior
of a system, if the data sets given by the system are not at all like the model
output, the identication may still be unsuccessful.
3.4 Optimization and software
Once the identiability analysis shows that the model is identiable,
identication still has to be done. As was said before, identication is a
problem that can be formulated as an optimization (minimization) of an
index measuring the error between the model output and the measurements.
A good example of an index to be minimized was shown in equation 3.1.
There are several algorithms that can be used to execute that minimization.
A quick review and classication of optimization algorithms will be now done.
The rst classication to be done is about local and global optimization.
The local approach assumes solution is in a region near to the starting point,
and that there is only one solution in that region that has to be found. The
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global approach does not consider regions, and assumes that there can be
several optimal points in there respective regions, but only one is the global
optima. Local algorithms are usually deterministic searchers, and are ecient
solving linear problems or adjusting linear models to experimental data.
In the case of the models seen in this thesis, global optimizers have to be
used because of the non-linearities and discontinuities the models present.
This kind of optimization problems needs of global optimizers, that usually
involve using stochastic sampling methods or multiple starting points using
deterministic algorithms. Also, the problem of identication is always bound
because the parameters cannot take any values imaginable. There are non-
negativity boundaries and theoretical stability limits in the values of certain
parameters (some values of certain parameters may make the model unstable.
This fact is very important in the choice of an algorithm to identify, for
the boundaries are usually treated as non-linearities, and thus non-linear
algorithms tend to be more prepared to deal with this kind of problems.
3.4.1 Nonlinear programming
The rst algorithm to be used for identication was a non-linear local solver
that ts into the group of solvers denominated as Nonlinear programming
solvers, or Constrained nonlinear optimizers. This sort of algorithms are
deterministic solvers that use rst and second derivatives of the objective
function, along with some heuristics to cope with the various problems that
deterministic local searchers have. Abundant information about this kind
of algorithms can be found in Coleman and Li paper of 1996 [18], Powell's
conference in 1978 [76], or for a more general reference see Bazaraa's book
[7].
The suite used is part of Matlab's Optimization Toolbox, which is
composed of many dierent searchers to solve any optimization problem
in the Matlab environment. The function used in the identication of
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postprandial models is the main nonlinear programming function in the
toolbox, the fmincon function. The use of this function has a major
drawback, due to its local scope. It usually gets stuck in local minima instead
of searching for the global optimum.
3.4.2 Scatter search for Matlab
Scatter search for Matlab (SSM from now on) is a global optimizer based
on statistical principles that has already been used in the articial pancreas
project, with the objective of patient identication, by Cesar Palerm in Santa
Barbara [64].
SSM optimizer is a project of the CSIC (Centro Superior de
Investigaciones Cienticas) and the university of Vigo. It is a global
optimizer, and as such it is easily comparable with genetic algorithms
[27]. Scatter search does not use codication of the population as genetic
algorithms do, but it does work generating new generations (ospring) of
the function optima by combining the properties of the previous (parents)
population. Plus, it does not generate random mutation on the population,
but it does renew the existing individuals by adding new random samples to
the new generations of optimal solutions. The details of the inner algorithms
are not going to be exposed in here. For the better understanding of the
searcher check out Julio Banga's group papers in 2006 [83] and 2007 [22].
This optimizer has the advantage of using local solvers to rene the search
when it seems to have found some optimum solution. The local solver to be
used can be chosen from a list available in the SSM's documentation. fmincon
is one of the many solvers available, so the use of SSM incorporates the use
of the other solver described before.
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Chapter 4
The Challenge of Model
Identication in Diabetes
Identication of a model in the articial pancreas context consists on
the characterization of a patient with a series of parameters. Those
parameters can be constant, time-varying, yes/no parameters, periodic,
etcetera. Parameterization of the patient is of common practice in diabetes
treatment heuristically estimated woth parameters such as:
• Insulin sensitivity. It is the decrease of glucose related to a certain
amount of insulin. It is one of the principal parameters for the
characterization of a diabetic patient, and it is subject to circadian
and long term variations. It determines rate of basal insulin to be
administered to a diabetic patient.
• Insulin to carbohydrate ratio. It is the amount of insulin required
to counteract a certain amount of ingested carbohydrates (CHO). It is
also subject to circadian and long term variations.
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These parameters can be heuristically determined by simple observation
of the patient, but there are other parameters in a diabetic mathematical
model that are representative of internal physiological processes, and their
quantication is not straightforward. Some of those parameters are:
• Endogenous glucose production.
• Glucose uptake by tissues.
• Glucose absorption rate.
• Insulin absorption rate.
• Insulin degradation rate.
These parameters are very dicult to characterize because their dynamics
are usually related to several hormone concentrations, and those relations are
usually subject to circadian and long-term variations. Furthermore, those
dynamics are not completely well understood, and proposed models are not
accurate. The dierence with the observable parameters described before
is that the quantication of the variations (especially the circadian) is very
dicult, and usually including complicated dynamics in the mathematical
models yields to non-identiable models.
One of the most complex models describing the physiology of diabetes
is the model seen in section 2.2.3, and its published simulator. That
model represent in a detailed manner physiological processes, describing the
dynamics with a set of equations, and reducing the patients characterization
to a set of constant parameters, shown in Table 2.23.
This model and the simulator developed by the University of Virginia
has been accepted by the FDA for controller testing in the context of a
clinical trial at Padova and Virginia. The FDA acceptance was not due to
the models capabilities on characterizing individual patients behavior but
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due to the set of virtual patients included, characterizing variability found
in a real population. The simulator is distributed with a non-disclosed set
of parameters that is able to simulate over 300 patients (100 children, 100
adolescent and 100 adults).
In this chapter, the ability of the model to test controllers is not discussed,
but the identiability of this model and its practicality when trying to
characterize a real patient.
A set of experimental data from several T1DM patients was available for
the use of the INSULAID2 project, which has already been used for real
time glucose estimation in continuous monitoring [46]. That data will be
used for model tting in order to prove Cobelli's model feasibility to adjust
to experimental data. The study included 18 patients with type 1 diabetes
following the protocol approved by the Dr. Josep Trueta University Hospital
of Girona's Ethics Committee. Patients were monitored for three days (one
day at the hospital and two days at home) using the CGMS Gold (MiniMed
CGMS). The CGMS Gold was applied to the subcutaneous abdominal region
of each patient and was used continuously for a period of 72 h. After the third
day, the monitor data were downloaded to a computer using the CGMS Gold
algorithm (Solutions Software 3.0). The CGMS Gold was calibrated with
capillary glucose measurements using conventional self-measurement of blood
glucose. During the rst day, plasma glucose was simultaneously measured
with a Beckman Glucose Analyzer every 15 minutes during 2 hours after a
meal and every 30 minutes otherwise. Plasma insulin was also measured.
4.1 Cobelli's model identiability
Prior to the experimental identication of the patients from the Josep Trueta
Hospital, the model's identiability is going to be analyzed. Previous work
on identiability of the insulin model was done by Ana Revert [80], given that
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plasma insulin data was also available in this study. The insulin submodel
was then considered known for several patients in which the identication
was successful, and the plasma insulin was considered as an input to the
model.
In this identication study, initial states were also considered as
parameters of the model to be identied. This was done in order to consider
the identication as a broader general case. Only the initial states of the
compartments of the glucose model were considered to be dierent to its basal
values, the rest of the initial conditions were considered equal to the basal
parameters (EGP, insulin delays, ...) due to the fact that at the beginning of
the day there are no previous insulin bolus or meals. The two new parameter
added are:
• Gp0 - Initial state for mass of plasma glucose.
• Gt0 - Initial state for glucose in the tissues.
Another variation has been included in the model in order to improve
identiability and to simulate patients with more accurate physiologic
conditions. The dawn eect is a well known rising in blood glucose in
diabetic patients after the night period [10] [71]. This phenomenon is
known to be caused by a decrease in insulin sensitivity during the night.
Insulin sensitivity is known to have circadian variations of dierent intensity
depending on the patient. A 24 hours periodic variation of insulin sensitivity
has been included into Cobelli's model, as shown in Figure 4.1, and two new
parameters have been added to adapt the variation depending on the patient:
• modsens - sensitivity variation's modulation. It amplies the variation
of insulin sensitivity.
• sensdelay - sensitivity variation's delay. It shifts the variation of insulin
sensitivity in time, advancing or delaying the peaks or the valleys of
insulin sensitivity depending on the patient.
98
Figure 4.1: Circadian variation over 24 hours in an average diabetic patient.
It multiplies insulin sensitivity. Extracted from [87]
Identiability analysis has been applied to this model for a three meals
scenario. The analysis was done following the scheme shown in Figure 3.2,
and results are shown in Table 4.1.
The table shows the evolution of each parameter coecient of variation
at each iteration of the sensitivity analysis. The rst iteration shown is the
rst one in which the FIM is not singular. The parameters in which no CV
is shown are the parameters that made the FIM singular. As can be seen,
all the condence intervals decrease as more and more parameters are xed
to their nominal values. Always the highest CV determines the parameter
to be xed.
At iteration 11, all the parameter CVs are under 0.3, which is the
threshold decided for identiability. The next iteration was performed due to
the correlation of two parameters. The correlation matrix for the parameters
left in the 11th column of Table 4.1 is that shown in Table 4.2. As can be



































































































































































































































































































































































































































































































































































































































parameters 16 and 17, the one that is lower in the ranking is parameter 16,
which results to be the one with the biggest CV as well. The decision taken
was then, xing parameter 16.
2 4 5 6 8 16 17 19 Ranking
2 1,00 0,02 -0,07 -0,16 0,88 0,60 -0,54 0,70 95,50
4 0,02 1,00 0,72 -0,12 -0,20 -0,25 0,26 -0,13 35,64
5 -0,07 0,72 1,00 -0,44 -0,04 -0,37 0,39 0,13 24,43
6 -0,16 -0,12 -0,44 1,00 -0,07 0,60 -0,69 -0,33 131,10
8 0,88 -0,20 -0,04 -0,07 1,00 0,71 -0,66 0,83 92,69
16 0,60 -0,25 -0,37 0,60 0,71 1,00 -0,98 0,41 48,62
17 -0,54 0,26 0,39 -0,69 -0,66 -0,98 1,00 -0,33 217,62
19 0,70 -0,13 0,13 -0,33 0,83 0,41 -0,33 1,00 22,97
Table 4.2: Parameter's correlations for the last iteration of the sensitivity
analysis. The last column is not part of the correlation analysis but the
ranking of the parameters in the most inuent eigenvalue of the FIM.
Starting from a model in which 20 parameters were characterizing a
diabetic patient, only 7 parameters remain identiable at the end of the
analysis. Identication of two real patients is going to be performed with
blood glucose for a whole day, and validation will be done by comparing
the results of simulating the two following days to the identication, and
comparing it to CGMS home data (no blood glucose data is available).
Cost ponderation for the tting is decided to be a diagonal matrix where
all the entries of the diagonal are equal to the maximum of the experimental
data, as explained in Chapter 3.
4.2 Experimental Data Fitting
In this chapter some examples of data tting are going to be shown and
discussed. The number of available patients was initially 22, but few of
those patients were possible to be identied in their insulin sub-model due
to anomalous absorption or high variability. Out of the patients that were
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successfully identied in their insulin sub-model, few of them were possible
to t accurately to the Cobelli's model. Many experimental identications
were performed, and only two of those data tting were satisfactory. The
tting of those two patients is shown in Figures 4.2 and 4.3.
Figure 4.2: Data tting of Cobelli's model to blood glucose experimental
data
In those gures the blue line represents the blood glucose data, and the
red line is the model prediction. In the rst identication, all three meals are
very well simulated by the identied model, as well as the general descendant
tendency of the day. In the second identication, the rst meal is not very
well tted, but the descendant tendency in the following hours is very well
captured. Both cases are successful in terms of similarity of the response and
repeatability of the optimizer. Several runnings of the optimizer were done
in order to prove a single solution. Other patients data were discarded due
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Although data tting was successful for two data sets, this does not mean
the model is useful. Model identication has to be validated with some data
dierent than the utilized for the identication. In the case of the data
available for this experiment, the Josep Trueta monitoring, the validation
data that was used was the CGMS data acquired at home in the two following
days to the hospital monitoring. The results of that validation are shown in
Figures 4.4 and 4.5.
Figure 4.4: Identication of a three days real monitoring. The rst day was
used for identication while the two last days were used for validation of the
identied model
In these gures several signals that are considered interesting for the
understanding of the model's behavior are plotted. The top graph is the
patient's glucose, now the red line being the CGMS signal, the blue line
being the identied model prediction, the pink line in the rst day being the
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Figure 4.5: Identication of a three days real monitoring. The rst day was
used for identication while the two last days were used for validation of the
identied model
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blood glucose data (already shown in previous gures), and the green spikes
being the meal ingest periods. The second graph (from the top) that is shown
in the gures is the plasma insulin prole from the model. It can clearly be
seen the times of the bolus infusions, and how the level of plasma insulin
increases drastically during meal times. There is also a basal level of insulin
assumed constant. The third graph is the endogenous glucose production,
which is an internal state of Cobelli's model and that is dependent on the
plasma insulin. The forth graph is the insulin sensitivity variation along the
three days of monitoring, as described before. The bottom graph is the rate
of appearance of glucose in blood as delivered by Dalla Man's model.
As it is clearly seen by Cobelli's model validations, even though the model
ts perfectly the identication data, it does not reproduce the validation days,
which is its main purpose. This is not an unexpected result, and the validity
of this model was questioned at every step. Anyway, a prediction horizon of 2
days, as was considered in the previous identication, is unrealistic, but given
that this work with Cobelli's model is a preliminary contact with modeling
in diabetes, it is a useful result. No model for diabetes has been proven
good for predictions of more than a two hours horizon, and only predictions
of populations, not single individuals. Following work on this eld will be
focused on the postprandial stage and it's prediction, with prediction horizons
of no more than 5 hours.
Cobelli's case study and its identiability study proves that the model
is too complex, even without attempting to identify the insulin subsystem.
Simpler models are going to be analyzed in the following, and Cobelli's
endogenous model will not be used anymore, except maybe in future work,
using the simulator for testing controllers.
Simple postprandial identication trials with Bergman's model were also
performed on the Josep Trueta's data with similar results. Bergman's model
identiability will be discussed in chapter 6.1. In this case, the insulin
submodel was also being identied, but the philosophy of identication was
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dierent. In order to avoid variations in the gastric emptying, and thus in the
gastric submodel parameters, the meals identied are the three breakfasts
of one patient, whom repeated the same breakfast for three days, even in
quantity of CHO. The fact of being the breakfast the meal identied was
also good due to the fasting state in which patients arrived to the beginning
of the meal, which is the most similar state to a steady state in a diabetic
patient. This time, two days were used for tting of the model, and one
was used for validation, as can be seen in Figure 4.6. All the data was
extracted from a CGMS in this case, in order to minimize the dierence
between identication data
Figure 4.6: Identication of a three meals real monitoring. The two rst
meals were used for identication, while the third was used for validation.
All the date was extracted from a continuous glucose monitor
In that gure, the blue lines represent the CGMS data, and the red lines
are the identied model response. The two graphs in the top of the gure
are the postprandial responses of the patient and the model to the breakfast.
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The same model is being tted to both breakfasts. The graph in the bottom
is the validation breakfast.
As can be seen, even with simpler models the validation of model
identication is tricky in diabetes. The reasons for this lack of repeatability
are many. The metabolic state of a person in terms of diabetic physiology
is not completely understood. Trying to reproduce consecutive days (meals)
with the same model, considering the models that are now published in
literature, may not be possible. Many parameters that are considered
constant in the endogenous models are variable with time, and not only
in a circadian manner.
Data provided may be not appropriate for identication, and that is
the reason why the Josep Trueta's data will not be used anymore in this
thesis. Instead, new sources of data will be used. Taking advantage of a
new collaborative way with the Hospital Clinic Universitari de Valencia,
possibility of new data acquisition arises. Plus, new models will be studied
and analyzed.
4.3 Critical selection of models
The identication problem in diabetes has been proven really dicult even
for the simplest models, like in the study of Ana Revert [80], or the pure
control approach of Stål [90] in Lund. The problem of the identication is
not about adjusting the data existing to the models provided. That task
is usually performed with success. But when using the model identied for
further simulations, models prove themselves mainly useless.
Of course, the main solution to this problem is to develop new, more
ecient models for the glucoregulatory system, but that is not the main
objective of this thesis. Instead, a critical review of the most used models is
going to be quickly done in the following lines.
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The fact that the set of Cobelli's group models is now accepted by the
FDA as a simulator of diabetes makes those models to look like the correct
choose to be used in research works like this thesis. Also Dalla Man describes
the gastric emptying of the stomach as a function of the fraction of glucose
in the stomach, being the only model implementing this feature, so this
was the model chosen to be the exogenous glucose model in this research.
While working on this thesis, there was a parallel research being done by
INSULAID2 (the research project in which this thesis is involved) with
the Willinska model, showing much better identiability results than with
previous work done with other models [80], and so this model was used for
the identiability and optimal experiment analysis.
When trying to choose an endogenous model the question is much trickier.
Following the same logic as before, reason dictates Cobelli's model has to be
chosen because of it's FDA acceptance. Willinska published a review of the
identiability of models for simulation [103], stating that Cobelli's model has
the problem of having too many parameters to be identied from clinical
data, what makes the identiability of the model to drop.
Minimal models (not used for simulation) such Bergman's or Panunzi's
model skip the problem of overpopulation of parameters, but obviously
describe with less accuracy glucose behavior. Bergman's model has been
strongly criticized in late years because of it's simplicity and the fact that it
does not t correct glucose behavior against insulin. Quon et al [78] proved in
1994 with a series of experiments involving the Biostator device that Bergman
model underestimates insulin action on glucose removal from blood, and it
overrates the eect of glucose concentration in its own disappearance (glucose
eectiveness).
In 1999, Regittnig et al. [79] conrmed the overestimation of glucose
eectiveness. They also proved that all minimal models are inevitably wrong
if they consist of one single compartment for glucose, without considering
the interstitial dynamics or other situations. Considering that a minimal
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model has to stay simple, let us take a closer look to the equations related
to the glucose compartment in minimal models, like the Bergman model.
Considering that there is no exogenous input of glucose, equation (2.73)
stands:
Ġ(t) = −p1G(t)−X(t)G(t) + p1Gb (4.1)
The part of the equation −p1G(t) is the term of the Bergman model that
represents the glucose eectiveness, and it depends directly on the parameter
p1, that has to be identied. The term p1Gb sets the equilibrium point of the
model to the basal glucose if insulin is at basal level and there is no glucose
input. The term X(t)G(t) is the insulin related term, applying insulin with a
delayed compartment. Looking at the equation of the glucose compartment
of another minimal model, the Panunzi model:




The term related to glucose eectiveness does not exist. The term related to
insulin input, −KxglI(t)G(t), is applied without a delay because Panunzi's
model was designed for healthy patients and the delay is considered in
the endogenous secretion of insulin. The term
Tgh
Vg
is similar to the
equilibrium point term in equation 4.1, both are constant terms that dene
the equilibrium point of the equation, but they are considered in dierent
ways. In the Bergman model, the basal level is stated explicitly, while in the
Panunzi model it is seen as a hepatic balance of glucose. Both approaches
are true and useful, and the identication is done in the same way in both
examples.
In this thesis, experiments will be performed with the Bergman model
because it is considered in diabetes research as a sort of benchmark model
to test any methodology, but every result will be compared with a variation
of Panunzi's model that will be explained in the following lines.
Bergman model has an odd behavior when simulating a diabetic patient
to whom basal insulin infusion is removed. The correct behavior to a empty
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insulin compartment in a diabetic patient is blood glucose to increase without
measure. In Figure 4.7 a simulation with Bergman's model is shown, with a
warming period of 10 hours in which the insulin infusion is stopped; then, at
minute 600, insulin infusion is restored, a 75 grams of a mixed meal ingested
(simulated by Dalla Man's model) simultaneously to a 7.5 units of insulin
injected as a bolus.
Figure 4.7: Bergman simulation of a change in basal level and nominal values
of glucose eectiveness
If there is an stop in basal insulin infusion with a smaller glucose
eectiveness, the results are shown in Figure 4.8.
The behavior observed in the warming period of the previous gures
is unrealistic. A diabetic patient whose insulin infusion is removed should
become an unstable process, not just change its equilibrium point. Panunzi's
model, in its equation (4.2) becomes a pure integrator if insulin is removed,
making the system unstably increasing. Panunzi's model seems more suited
to the physiology of glucose in this case, but it also has its disadvantages. As
it was said before, the Panunzi model represents the delay of insulin action
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Figure 4.8: Bergman simulation of a change in basal level and 50% reduced
glucose eectiveness
in the equation of secretion, but that equation (2.75) is eliminated when
simulating diabetic patients, so the delay eect is removed. This results in a
faster acting of the bolus insulin in front of the simultaneous meal ingestion,
making blood glucose to drop inmediately after the injection, as can be seen
in Figure 4.9.
This phenomenon can be easily avoided by adding a delay equation (4.4)
to Panunzi's model, resulting in the next model:




Ẋ(t) = −ki[X(t)− I(t)] (4.4)
With the addition of a new parameter to the model. This new parameter has
to be set to a new nominal value, and it is going to be done by bibliography
review. In [29] Helms quanties the insulin action delay with a 20 minutes
settling time, which makes the parameter ki to be approximately equal to
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Figure 4.9: Panunzi's simulation of a meal at minute 120
0.08 min−1. The response to a meal and a bolus in that case is shown in
Figure 4.10, where the dropping of glucose just after the bolus time is almost
non present.
The shown model is completely satisfactory for identication purposes
and control. There is one last check to be done to the model to prove
its reliability. In their paper of 1994 [95], Torlone et al. showed a series
of experiments in which insulin bolus is injected some minutes prior to a
intravenous glucose infusion. This experiment shows clearly the eect of
insulin, and how it makes glucose to drop an impulse response behavior. In
Figure 4.11 this behavior is shown for almost one hour before the glucose
infusion starts.
In the previous gure it can be seen that there is no change in blood
glucose until 15 minutes after bolus injection, and then glucose drops for 30
minutes until approximately 70 mg/dl (approximately 3 mmol/l). In the
case of simulation with the Panunzi model with delayed insulin action, the
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Figure 4.10: Variation of Panunzi's model simulation of a meal at minute
120
results are shown in Figure 4.12, in which no intravenous glucose infusion
was simulated.
In simulation, the response is exactly as expected: no signicant change in
blood glucose in the rst 15 minutes, and in the next half hour, glucose level
drops to almost 70 mg/dl. This makes the new model much more reliable
than Bergman or Panunzi's models, and as such it will be used in this thesis.
Another simple feature was included in the modied Panunzi model.
Endogenous hepatic glucose production is one of the parameters of the model,
Tgh, and it is considered constant. This is actually not true, for endogenous
hepatic production is suppressed by insulin. A simple variation of the model
was introduced, considering the Tgh parameter to be reduced when plasma
insulin surpassed a dened threshold:
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Figure 4.11: Insulin impulse response of glucose after bolus and counteraction
with intravenous glucose infusion [95]. Black dots are the blood glucose
measurements for monomeric insulin analog, and the white dots for human
insulin
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Figure 4.12: Variation of blood glucose (mg/dl) in Panunzi's model





Tgh if Ip < 30 mIU/l
0.1 ∗ Tgh otherwise
(4.5)
In summary, one model was chosen for simulating purposes between the
so called models for simulation. That is Cobelli's model, which is the one
accepted by the FDA as a valid simulator, as seen in Chapter 4.1. Out of the
minimal models, two were chosen: Bergman's model, because it is probably
the most used model in diabetes research for the las 20 years, and it has been
studied and compared thoroughly, and also a variation of Panunzi's model





In the diabetes research scenario, the fact of performing experiments is a
high-cost, time consuming task that has to be thoroughly planned in order
to obtain the biggest benet out of it. In the case that is being reviewed
in here, the objective of that planning is to get the models to be easier to
identify. There are some methods that will help the researcher to obtain
the best identiability of a given model, choosing from a constrained set of
possible experiments.
An experiment of data recollection in diabetes initially has innite number
of variables that can change under dierent circumstances. The models
chosen is the rst choice to be made, and it is not an obvious one. In
this thesis case the models have already been chosen, but for the optimal
experiment design only the two minimal models will be used. The reason
of that decision is simply of computational eort. The experiment design
implies solving optimization problems whose computation times depends on
the complexity of the models, and those times are usually very long.
The design of an optimal experiment usually consists of the following
steps:
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1. Dene an optimality criterion related to the nal purpose of the
modeling, in this case optimal identiability, via a scalar cost function.
2. Take into account all constraints on feasible experiments.
3. Optimize the chosen cost function with respect to the experimental
variables available to the experimenter.
The experiment design will usually result in a non-linear constrained
optimization problem and thus, global optimization solvers will be needed
in order to nd the solution. In this chapter there will be a justication
of the optimal experiment design in diabetes, followed by the formulation
necessary to dene the criterion of optimality for identication. Finally
results of optimal designs will be shown.
5.1 The need of optimal design
There is a classical example seen in [99] that explains very clearly the need of
optimal design for almost every experiment to be performed. That example
will be reproduced in the following lines, showing that usually the intuitive
approach for experimentation is not optimal.
Example.-





and w∗3 to be estimated. The spring balance used for this purpose produces
a biased random measurement error, dened by a Gaussian distribution
N (0, σ2) and the measurement bias w∗0. Only four measurements can be done
in this experiment.
Intuition dictates to do the rst of the measurements y(0) without any
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object on the balance, in order to characterize the bias, and then have the
other three resting measurements for each of the objects. In that case the
estimates of the weight for each object is ŵi = y(i)− y(0), i = 1, 2, 3. The
estimates in this case are unbiased (which is very good), and have variances
var(ŵi) = 2σ
2 and covariances cov(ŵi, ŵj) = σ
2, i 6= j.
Another case has to be considered now. If the rst measurement is now







the estimates of the weights for the objects are:
ŵi =
y(0) + y(i)− y(j)− y(k)
2
, i = 1, 2, 3, i 6= j, i 6= k, j 6= k (5.1)
In this case, the variances of the estimators, which is a good approximation
of the identication performance, are var(ŵi) = σ
2 and its covariances
cov(ŵi, ŵj) = 0, i 6= j. Compared to the rst intuitive approach, this second
approach yields to a more accurate estimation and independent estimates,
plus the estimation is also unbiased.
In the context of the articial pancreas there are few published examples
of experiment design, and even fewer of them are based on the optimality
of the experiment in terms of identiability. One of the earliest attempt to
improve the identication in an endogenous model was carried out Cobelli
in 1986 [17]. The approach is based in the FIM methodology that will be
explained in Section 5.2, and it is the same method that will be used in
the work done in this thesis. Cobelli though, used a simplied version of
experimental design evaluating only the identiability of single parameters
instead of evaluating the identiability of the model as a block, combining
the identiability of dierent parameters.
There are several examples of modied standard protocols to perform
better identications, like the work of Percival et al. [70] where it is proven
that simply by separating the instants of insulin bolus injection and the
beginning of the meal the identication of a model is improved. However, no
theoretical study is presented with this regard.
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Only in the last years publications have appeared with complete
identiability studies and optimal design for the identication in diabetes.
Galvanin [26] published a study of optimal experiments based on Hovorka's
model, checking identiability involving meal ingestion or oral glucose intake,
yielding in quite complex insulin infusion rates like the one shown in Figure
5.1.
Figure 5.1: (a) Glucose concentration proles predicted by Hovorka's model
(dashed line) and after identication (solid line). (b) Insulin infusion rate
designed for the identication. Extracted from [26]
Given the huge problem that identication of models supposes in the
articial pancreas environment, it seems logical to ease the problem as much
as possible. In this thesis work several approaches to optimal experiment
design based on dierent models using the FIM methods will be carried out
as stated in Section 6.
5.2 Methods based on the FIM
The aim and need of the experiment design is now clear, and the question of
how to perform that design arises. So far, identiability has been analyzed
as a property of a parameter, quantied as the condence interval in the
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estimation of each parameter. That information is obtained from the Fisher
Information Matrix (or better said from its inverse), which summarizes the
information of all the parameters of the model for a given experiment. The
problem of optimal design can be expressed then as an optimization problem
of nding the minimum value of a certain scalar function of the FIM. That
function is called optimality criteria, and its general expression is:
j(Ξ) = φ[F (p,Ξ)] (5.2)
where φ is a scalar function. The evaluation of the Fisher Information Matrix
is a function F of p, the parameters vector, and Ξ, the experiment conditions
to be optimized.
There are several criteria that can be used in this case, as seen in [25]:
• D-optimality, in which the scalar function chosen is the determinant of
the FIM. The three following equations are equivalent, and all of them
dene the D-optimality criterion and whether it has to be maximized
or minimized in order to improve identiability:
Ξ = argminΞ jD(Ξ) = argminΞ det(F
−1(p,Ξ)) (5.3)
Ξ = argmaxΞ jD(Ξ) = argmaxΞ det(F (p,Ξ)) (5.4)
Ξ = argmaxΞ jD(Ξ) = argmaxΞ ln(det(F (p,Ξ)) (5.5)
• E-optimality, in which the function is the smallest eigenvalue of the
information matrix, and it has to be maximized.
• A-optimality, in which the problem is solved by maximizing the trace
of the information matrix.
In order to better understand the meaning of each one of these criteria,
spatial analogy is needed. If every parameter is placed in an axis of the
space, then the region dened by the condence intervals of each one of the
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parameters denes an ellipsoid the axis of which are given by the eigenvalues
of the inverse of the information matrix. Given that the objective of the
optimization is to minimize all the regions of condence, every axis of the
ellipsoid have to be minimized, or equivalently, the volume of the ellipsoid has
to be minimized, and that volume is exactly the determinant of the inverse of
the FIM. The rest of the criteria have similar meanings that are summarized
in Figure 5.2.
Figure 5.2: Each criterion reduces the condences intervals attempting to
minimize one singular scalar value [25]
The question of which criteria to be used arises now. The D-optimal is
the most used of the three standard criteria cited above. This is due to some
exclusive appealing properties of the criterion [25]:
• Easy geometrical interpretation, as seen in Figure 5.2.
• Invariance with respect to non-degenerated transformation applied to
the model parameters, such as rescaling. This property is applied in
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equation (5.5) in order to work, during the optimization process, with
smaller quantities.
• Yielding to optimal experiments which correspond to replications of a
small number of dierent experimental conditions.
• Optimal experiment design yields to non-singular FIM.
The main drawback this criterion has is that it gives too much importance
to the parameter to which the model is most sensitive. Geometrically, this
problem is equivalent to the idea of trying to minimize the volume of the
ellipsoid by reducing mostly its bigger axis.
There are other criteria available for dierent purposes, like the modied
E-optimality, that tries to maximize the FIM condition number, aiming
to make the condence ellipsoid as spherical as possible [97]. The correct
application of this criterion would be in a case of strong parameter
correlations, and the design will yield to a decoupled identication in
parameters.
That is not the case in this thesis though. D-optimality will be the one






The rst task to be done when designing an experiment is to determine
what parameters is the experiment going to be based on. The model for the
experiment design is excited by its inputs. These inputs are the variables that
can be adjusted in the experiment. For obtaining an optimal experiment,
the best combination of the inputs have to be found, regarding at the
identiability of the model.
Another variable usually considered in the optimization of the inputs
is the sampling period of the measurements. In the experiments to
be performed in here, the measurements are taken with the Continuous
Glucose Monitoring System (CGMS), so the measurements are taken with
the sampling period of the monitor, and its number increases with the
experiment. The problem is then about how long the experiment should
last. Usually, identiability of the model increases as the samples do, so the
boundary of the experiment time is not of identiability issues but of the
patient's comfort. It was decided that the time of the experiment was to be
xed at ve hours after a meal.
The inputs of a complete glucoregulatory model are two, the meals and
the insulin infusion (supposing insulin pump treatment). The complexity of
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the meal absorption and the absence of satisfactory models has historically
made meals to be considered as a disturbance, but in this work it is treated
as an input to be designed. Insulin is considered as an input as well. Both
inputs can be parameterized as:
• Parameterization of the meal.
1. Meal size
2. Meal composition
• Parameterization of the insulin.
1. Insulin bolus size
2. Insulin bolus time (relative to meal time)
3. Basal infusion rate
In order to parametrize the meals that patients have to eat there are two
variations that can be done. One is the size of the meal, and the other is
the composition. In the digestive model being analyzed in here, the Dalla
Man model, the set of parameters published were identied under specic
conditions listed below:




• Glucose: 90±5 g
The grams of glucose represent the size of the meal. The rest of the
parameters are supposed to determine the gastric emptying prole, and
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the identication performed in [20] transform the composition of the meal
in the parameter values shown in Table 2.18. Unfortunately, no further
identications have been performed on this model. Therefore, if one looks
for better identiability of the model, the experiments should be performed
with similar composition as shown. The size of the meal is going to be one
of the parameters for the experiment design.
Considering the insulin input, it is much more complex than the meal
ingestion, which is only considered as an impulse. The insulin pump
treatment can have any shape imaginable respecting the pump limitations.
Designing an absolutely free insulin prole, i.e. a non-parametric input,
would be too expensive in computational terms (for more information see
[99]), so a parametric input is chosen. The usual prole of basal-bolus
infusion is preserved in this experiment design for simplication purposes
and to increase the patient's compliance in the experiment design.
Once decided that a traditional treatment is going to be followed, the
only parameters to be chosen are the amount of insulin to be given in the
bolus, the basal insulin level, and the instant the bolus is administered. Basal
variations during meal time were considered at rst, but the importance of it
in the postprandial response is negligible. The experiment conditions chosen
to be optimized are, thus:
• τ - Delay of the insulin bolus with respect the meal time, in minutes. A
positive delay means that the insulin dose will be given after the meal
and vice versa. The boundaries for the optimization problem are set
to -60 and 300 minutes. Maximum advancement of the insulin bolus is
dened so as to prevent hypoglycemic events.
• Meal - The size of the meal in grams of carbohydrates. The boundaries
for the optimization problem are 0 and 100 grams of carbohydrates.
• Bolus - The amount of bolus insulin units to be given. The boundaries
for the optimization problem are 0 and 10 insulin units. These
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boundaries were chosen using an insulin-to-carbohydrate ratio of 1:10
as population mean.
Only one meal per day is considered due to the circadian variation of insulin
sensitivity. The vector Ξ is then a vector of size 3nd, where nd is the number
of days of monitoring. This vector is the output of the experiment design.
Given that the problem is highly non-linear (due to non-linearities of the
index and the model) SSM global optimizer is used to obtain the solutions.
The constraints for the optimization problem are the restrictions of the
blood glucose in order to keep the patient under safe health conditions. The
simulation was forced to start from equilibrium in a blood glucose level of 100
mg/dl. The maximum level of glucose (hyperglycemic bound) was set to 250
mg/dl and the minimum level (hypoglycemic bound) was set to 70 mg/dl.
These boundaries have to be respected at all times during the experiment
design.
Next, several results for experiment design in diabetes for dierent models
are shown. Despite the fact that Bergman's model has been proven unreliable
for simulating some glucose dynamics, it is desirable to try the experiment
design varying the models used in order to make the experiments as less
model-dependent as possible. That is why the rst experiment design shown
is calculated for this model. After that, two experiments designed for the
modied Panunzi model are explained.
6.1 Bergman's model identiability
Initially, Bergman's endogenous model has only three parameters to be
identied, but two more are going to be added to the study, the distribution
volume and the basal glucose. Bergman's endogenous model combined with
Dalla Man's glucose absorption model and Willinska's insulin subcutaneous
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model sums up a total of 17 parameters, described in Table 6.1.
Model Number Parameter Meaning
Endogenous 1 p1 Glucose eciency
2 p2 Insulin action rate of disappearance
3 p3 Insulin action rate of appearance
4 V olg Distribution volume of glucose
5 Gb Basal glucose
Gastric 6 Kabs Glucose absorption rate in the gut
7 Kmax Maximum gastric emptying
8 Kmin Minimum gastric emptying
9 b Involved in the gastric emptying
10 d Involved in the gastric emptying
Insulin 11 Vi Distribution volume of insulin
12 k Proportion of insulin in the slow channel
13 ka1 Transfer rate in the slow channel
14 ka2 Transfer rate in the fast channel
15 ke Insulin elimination
16 VMAX,LD Michaelis-Menten parameter
17 kM,LD Michaelis-Menten parameter
Table 6.1: Parameters to be identied in Bergman's model
Considering only blood glucose as the measurable output of the system,
and a three days experiment as the identication period for the reasons
explained before, all the parameters are not identiable (as expected).
Sensitivity analysis previous to the experiment design was performed, and
the results are shown in Table 6.2.
As the results of the sensitivity analysis show, many of the parameters of
the model are not identiable. The parameters that are xed in the initial
iteration of the sensitivity analysis are parameters that present a priori non-
identiability, therefore, parameters that make the FIM non invertible. That
is the reason for the absence of CVs of the rest of parameters, for those
coecients of variation are calculated from the inverse of the FIM.
Once the FIM was made invertible, only two more parameters had to
be xed to make the model identiable. The nal number of parameters
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Number Parameter
1 p1 - - -
2 p2 - - -
3 p3 - - -
4 V olg 0,25 0,14 0,13
5 Gb 0,12 0,08 0,07
6 Kabs - - -
7 Kmax 0,25 0,24 0,23
8 Kmin 0,42 - -
9 b 0,16 0,12 0,04
10 d 0,20 0,18 0,09
11 Vi - - -
12 k 0,34 0,33 -
13 ka1 0,31 0,22 0,09
14 ka2 - - -
15 ke 0,22 0,14 0,12
16 VMAX,LD - - -
17 kM,LD - - -
Table 6.2: Bergman's model parameter coecient of variation (CV) for
a three meals identication. Each column represents an iteration in the
sensitivity analysis, and parameters that don't have CV are xed due to
non-identiability
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identiable, out of the initial 17, is 7. Only two of those parameters are part
of the endogenous model, while three of them characterize the gastrointestinal
model, and the other two are part of the insulin model, as can be seen in
Figure 6.1
Figure 6.1: Total number of parameters identiable in Bergman's model
Those 7 parameters are the ones used to calculate model's identiability
in the experiment, thus the only ones involved in the calculation of the cost
index for optimal design.
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6.2 Experiments designed with Bergman's
model
Experiments with Bergman's model were designed considering only the set
of parameters decided optimum by the sensitivity analysis, and for a range
of experiment days from 1 to 4 days. At the end of the experiment design
for all the models under study, the best option was chosen from within of all
the experiments designed, including the dierent options of parameter sets,
models, and length of the experiments.
The results of an experiment designed for only one day of monitoring
consisting on the ve following hours to a meal is shown in Table 6.3.
Experiment Units Day 1
τ minutes -31,59
Meal gr CHO 100
Bolus IU 10
Table 6.3: Experiment designed for Bergman's model considering one day of
monitoring
As it can be seen, in the case of only being able of monitoring one day, the
optimum experiment to be followed by the diabetic patient is to advance the
bolus approximately half hour, and then eat 100 grams of carbohydrates. It is
worth remembering that 100 grams of carbohydrates is the top value given to
the optimizer for the experiment design. Also, 10 is the top boundary for the
bolus variable in the optimization, and it is the corresponding value of insulin
for an standard treatment of insulin boluses for a 100 grams of carbohydrates
meal. This means that, in addition to maximizing identiability of the model,
the experiment design keeps the patient under good glycaemic control.
The Bergman's model response for the experiment described can be seen
in Figure 6.2.
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Figure 6.2: Bergman's model response to the proposed experiment for 1 day
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The model's response shows a very quick response of the blood glucose
to the advanced insulin bolus, falling quickly to a level of approximately 70
mg/dl. This level is the safety threshold indicated to the optimizer to keep
the patient under safe conditions. That means that the optimizer is moving
the signal utilized for identication to the limits, and then rising it up to the
highest level it can, but always keeping the (virtual) person in safe levels.
The results of the experiment designed for two days monitoring are shown
in Table 6.4.
Experiment Units Day 1 Day 2
τ minutes 25,23 -29,58
Meal gr CHO 86,81 100
Bolus IU 10 10
Table 6.4: Experiment designed for Bergman's model considering two days
of monitoring
In this new experiment two dierent therapies are applied to the patient.
The second day is the same case as in a single day experiment. In the rst
day of identication, a bolus of 10 insulin units is delayed approximately 25
minutes, for a meal of 86.81 grams of carbohydrates. Now the proportion
of insulin units to grams of carbohydrates is not maintained. Now the
proportion of insulin units to grams of carbohydrates is not maintained, and
thus, not a good glycaemic control os performed on the patient (including
the eect of the delay).
The model response for the designed two days experiment is shown in
Figure 6.3.
Observing the rst day response of the model to the proposed experiment,
the fact of non-proportionality of insulin to carbohydrates makes more sense.
The model moves from 250 mg/dl down to 70 mg/dl, which are the top and
bottom thresholds in the experiment design. The optimizer is trying to move
the identication variable (blood glucose) in all the range that is possible, so
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Figure 6.3: Bergman's model response to the proposed experiment for 2 days
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to maximize identiability. Given that in the rst day, due to the delay of
the insulin bolus, there is no falling of the blood glucose to the lowest level,
it has to drop to that level after the meal, that is why the insulin bolus is
still relatively big with respect to the size of the meal. Given those values,
the maximum amount of carbohydrates for that meal is 86.81.
It is interesting to understand why the two days dier in the time in which
the bolus is administered. In the rst day, no insulin variation is given for
approximately 30 minutes, and so, all the information extracted from that
period is only increasing identiability for the other input model, the Dalla
Man model. In the other day, the opposite situation is happening. Only the
insulin subcutaneous model is experimenting variations, so information is
being created for the parameters of that model. The strongest the variation
of the states of the model in that period, the greater the identiability will
be.
The experiment designed for the case of a three days monitoring is shown
in Table 6.5.
Experiment Units Day 1 Day 2 Day 3
τ minutes 26,43 -30,44 -30,71
Meal gr CHO 85,60 100 100
Bolus IU 10 10 10
Table 6.5: Experiment designed for Bergman's model considering three days
of monitoring
In this case, the advancing of the bolus is repeated two days. Given that
the meals does not have to be consecutive, or that one day does not have any
relation to the others, the order of the experiment days is not important for
the result of the experiment.
Model's response to the experiment proposed is shown in Figure 6.4.
The second and third days are virtually the same, and the rst one is again
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Figure 6.4: Bergman's model response to the proposed experiment for 3 days
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rising and falling to both boundaries. It is again clearly seen the separation
of dynamics.
The four days experiment results are shown in Table 6.6.
Experiment Units Day 1 Day 2 Day 3 Day 4
τ minutes 25,44 14,36 -29,92 -30,88
Meal gr CHO 86,81 99,64 100 100
Bolus IU 10 10 10 10
Table 6.6: Experiment designed for Bergman's model considering four days
of monitoring
In this case the last days are repeated again with the advance of the
insulin bolus, and a new delayed bolus prole appears, but in this case with
a big meal. The delay on the bolus is smaller so that the meal can be bigger,
improving this way the identiability of the Dalla Man model.
The response of the model for the four days experiment is shown in Figure
6.5.
As it can be observed, there is not much dierence in the rst two days
of identication because the dierence in the meal size is relatively small.
The most relevant observation of this experiment design with the
Bergman model is that separating dynamics is the key to improve the
identication. It is better for model's general identiability to advance the
bolus rather than having it delayed, but the best situation is to have both
situations in an experiment of 2 days minimum.
The number of days of the experiment has to be selected paying attention
to both identiability and conditions of the experiment. It has been stated
that a minimum of two days for monitoring seems reasonable for identication
purposes due to the two dierent proles of experiment. In Figure 6.6 and
6.7 evolution of identiability of each parameter of Bergman's model can be
observed for all the cases exposed.
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Figure 6.5: Bergman's model response to the proposed experiment for 4 days
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Figure 6.6: Bergman's identication parameters and its coecients of
variation as they get smaller with the number of monitoring days
Figure 6.7: coecients of variation of Bergman's parameters for the
experiments designed as they get smaller with the number of monitoring
days
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It can be clearly seen that a sudden falling of the coecient of variation
happens when the monitoring days increases from one to two. After that,
identiability of all the parameters keeps increasing, but more slowly. Similar
tendencies are observed for the identiabilities of the parameters in the case of
applying the experiment design, but the levels of the coecients of variation
of the same parameters are much lower. The comparison of coecients of
variation before and after optimal design is shown in Figure 6.8.
Figure 6.8: A comparison of identiability for each parameter with and
without the experiment design for the case of a three meals monitoring
A remarkable fall in the coecient of variation is observed for all the
parameters, although to a dierent extent.
A three-day experiment was chosen thinking on clinical implementation
of the experiment design. It is desired to have as many identication days
as validation days, which makes the real monitoring period twice as long as
the experiment designed. Given that the average life period of a continuous
glucose monitor is around one week, the three days experiment was chosen (in
this case) as monitoring duration, for maximizing the identiability. Results
have to be compared with other models experiment design to make the
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experiments as less model-dependent as possible.
6.3 Modied Panunzi's model identiability
The modied version of Panunzi's endogenous model described in Section
4.3 is going to be tested, starting with its identiability. In this case the
parameters of the model to be identied are 16, including the 4 corresponding
to the endogenous model. The 16 parameters are described in Table 6.7.
Model Number Parameter Meaning
Endogenous 1 Kxgl Insulin sensitivity
2 Vg Distribution volume of glucose
3 Tgh Hepatic balance
4 ki Insulin action delay
Gastric 5 Kabs Glucose absorption rate in the gut
6 Kmax Maximum gastric emptying rate
7 Kmin Minimum gastric emptying rate
8 b Involved in the gastric emptying
9 c Involved in the gastric emptying
Insulin 10 Vi Distribution volume of insulin
11 k Proportion of insulin in the slow channel
12 ka1 Transfer rate in the slow channel
13 ka2 Transfer rate in the fast channel
14 ke Insulin elimination
15 VMAX,LD Michaelis-Menten parameter
16 kM,LD Michaelis-Menten parameter
Table 6.7: Parameters to be identied in Modied Panunzi's model
Many of the parameters involved in the sensitivity analysis for Bergman's
endogenous model, in particular those of the insulin and intestinal submodels,
are repeated in this model, but the numeration is dierent due to the
dierent number of parameters in the endogenous model. The results of
the identiability study are shown in Table 6.8.
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Number Parameter
1 Kxgl 2,95 1,14 0,98 0,55 0,53 0,31
2 Vg 0,70 0,46 0,43 0,26 0,24 0,23
3 Tgh 0,55 0,51 0,18 0,18 0,18 0,06
4 ki 4,93 4,91 - - - -
5 Kabs 2,00 1,60 1,12 0,67 - -
6 Kmax 0,95 0,78 0,66 0,53 0,24 0,24
7 Kmin 1,27 0,87 0,68 0,33 0,33 0,30
8 b 0,43 0,41 0,20 0,18 0,17 0,13
9 c 0,87 0,66 0,51 0,34 0,20 0,18
10 V 6,47 - - - - -
11 k 1,16 0,91 0,81 0,36 0,29 0,27
12 ka1 0,74 0,45 0,43 0,26 0,25 0,20
13 ka2 6,17 3,77 2,57 - - -
14 ke 3,36 0,88 0,71 0,49 0,49 0,30
15 VMAX,LD 1,96 1,92 0,92 0,66 0,62 -
16 kM,LD - - - - - -
Table 6.8: Modied Panunzi's model parameter coecients of variation (CV)
for a three meals identication
In this case, only two parameters were not identiable because of FIM
singularity, parameters 10 and 16 which have their respective rows in the
previously mentioned table in blank. Parameter 16 is discarded because its
low sensitivity, and parameter 10 is xed to its nominal value due to a very
strong correlation (actually, it has a proportional relation) to parameter 1.
Even though the threshold for identiability was xed at 30% of variation,
the set of 10 parameters on the last column of Table 6.8 is considered the
optimum set of parameters for the modied Panunzi's model proposed. There
are three parameters that are in the limit of the proposed identiability: Kxgl,
Kmin and ke. Of those three, the most critical one (greater variation), which
is the insulin sensitivity Kxgl is very important to be identied since it is a
physiological parameter that suers huge variations between patients, and
it is key in patient's treatment. The other two parameters are in the limit
of their own identiability, so it was decided to treat them as identiable
parameters. The summary of identiable parameters is explained in Figure
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6.9.
Figure 6.9: Total number of parameters to be identied in the modied
Panunzi's model
These 10 parameters will be used in the experiment design for the
calculation of the index of total identiability of the model.
6.4 Experiments designed with modied
Panunzi's model
Two dierent sets of parameters are considered in the experiment design of
this model. The rst set of parameters is the one concluded as optimum for
the model's identiability, as shown in the previous section. In that set the
parameter Kabs, key for the intestinal absorption characterization, was not
included. The other set of parameters includes the parameter Kabs in the
identication, which is the constant rate of absorption of glucose from the
gut to the blood. This parameter has a great physiological importance in the
understanding of how dierent meals can be absorbed by the gastrointestinal
tract, and it is supposed to be related to the composition of the meal. Due
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to its importance, it is decided that Kabs is forced to be identied, creating
a new set of parameters called suboptimal set of parameters, as shown in
Figure 6.10.
Figure 6.10: Suboptimal set of parameters to be identied in the modied
Panunzi's model
Two parameters are not being considered in the suboptimal set that were
being identied for the optimal set, those are Vg and ke. These parameters











Table 6.9: Panunzi's model suboptimal parameters coecients of variation
(CV) for a three meals identication
Anyway, the rst set of parameters that is going to be considered for the
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experiment design is the optimal one, described in Section 6.3. The results
for the experiment designed for one day is show in Table 6.10.
Experiment Units Day 1
τ minutes -17,959
Meal IU 10
Bolus gr CHO 100
Table 6.10: Experiment designed for Panunzi's model considering one day of
monitoring and the optimal set of parameters
The same prole as in the Bergman's model experiment design is observed
in this case. The advance in the insulin bolus is a little smaller, but the meal
and bolus size is again maximum. The response of the new model to the
experiment designed is shown in Figure 6.11.
Comparing modied Panunzi's model response in a single day experiment
with the Bergman's model response, the glucose prole is virtually identical.
That somehow, proves the independence of the results of the experiment
design from the model used to calculate them. Of course the parameters
being identied are not the same in one or other model, but the signal
from where information is being extracted is the same, and thinking about
that signal from an theoretical point of view, an optimal signal in terms of
information for one model, must contain big amounts of information for any
other model too. That is why it is expected of optimal experiment results to
be similar for the new model to the results for the other experiments already
designed.
The experiment design results for a two days experiment can be seen in
Table 6.11.
The second day in this experiment is the same as the single day
experiment, in which the bolus is administered in advance to the meal time,
thus only the insulin system is being identied in that case. In the rst day,
a new situation is proposed, similar to the case of Bergman's design in which
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Figure 6.11: Modied Panunzi's model response to the proposed experiment,
with its optimal set of parameters, for 1 day
Experiment Units Day 1 Day 2
τ minutes 157,80 -17,92
Meal gr CHO 44,25 100
Bolus IU 3,07 9,99
Table 6.11: Experiment designed for modied Panunzi's model considering
two days of monitoring and the optimal set of parameters
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the bolus was delayed, but in this case, the delay is much bigger. However,
delaying the insulin bolus up to two hours and a half can be quite dangerous
for the patient because of risks of hyperglycemia.
In Figure 6.12 the response of the model to the experiment proposed can
be observed.
Figure 6.12: Modied Panunzi's model response to the proposed experiment,
with its optimal set of parameters, for 2 days
In the case of the rst day can be observed that the small amount of
carbohydrates given to the patient (44,25 grams) have the objective of rising
the blood glucose up to the superior limit of safety of the patient. The insulin
bolus is given when the blood glucose gets to the maximum established, and
the amount of insulin given is so that will make the blood glucose to fall to
the inferior limit of safety. Again, the experiment design is moving the signal
used for identication from one boundary to the other, in order to maximize
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the amount of information.
Bergman's model was probably not able rise so fast up to the limit of
hyperglycemia due to the so called term of glucose eciency (as explained
in Section 4.3) that makes glucose to fall automatically when it rises above
the stability point.
The results of the three days experiment can be seen in Table 6.12.
Experiment Units Day 1 Day 2 Day 3
τ minutes -17,83 -18,42 165,74
Meal gr CHO 100 100 44,38
Bolus IU 10 10 3,01
Table 6.12: Experiment designed for modied Panunzi's model considering
three days of monitoring and the optimal set of parameters
In this case the advanced bolus administration is given in two out of the
three days of the experiment, while the other day a small meal is given, with
the insulin bolus delayed 2,5 hours, just like in the two days experiment.
The response of the model is shown in Figure 6.13.
This is a very good example of how the dierent experiments designed
for each independent day are not dependent on the order of those days.
Sometimes the case of the small meal and delayed bolus is in the rst day,
some others at the end, and it can also be in the middle of the 3 days.
The nal case of the experiment design with 4 days and the optimal set
of parameters, is shown in Table 6.13.
The last day is a little bit dierent than the previous ones, but it hardly
denes a new type of therapy for a day of identication. It is a variation of
the prole with a small meal and delayed insulin bolus, only that the delay is
smaller so that the insulin bolus has not only a role of correction of the level
of blood glucose, but also tries to counteract the rise of blood glucose that
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Figure 6.13: Modied Panunzi's model response to the proposed experiment,
with its optimal set of parameters, for 3 days
Experiment Units Day 1 Day 2 Day 3 Day 4
τ minutes 167,06 -17,22 -18,41 86,19
Meal gr CHO 44,25 100 100 47,07
Bolus IU 3 10 10 4,13
Table 6.13: Experiment designed for modied Panunzi's model considering
four days of monitoring and the optimal set of parameters
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is still coming from the gut. That is observed in Figure 6.14, where the time
of administration of the bolus does not wait for the blood glucose to stop
rising and get stabilized, and instead, it forces it down before the absorption
is over.
Figure 6.14: Modied Panunzi's model response to the proposed experiment,
with its optimal set of parameters, for 4 days
As a summary, with the optimal set of parameters of the modied
Panunzi's model, two dierent proles of glucose are determinant for the
good identication of the model.
• The rst therapy has already been seen in Bergman's model experiment
design, and it consists of an advance of the bolus of insulin to the meal
time, improving this way the identiability of the insulin subsystem.
• The second therapy is a big delay (2-3 hours) in the administration of
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the bolus, while giving a small amount of carbohydrates (40-50 grams)
to avoid excessive hyperglycemia. In this way, separation of insulin and
glucose dynamic from the meal is obtained, while maintaining plasma
glucose in a safe range.
In Figures 6.15 and 6.16 the evolution with the number of days of the
parameters identiability is shown for the optimal set of parameters.
Figure 6.15: Modied Panunzi's optimal set of parameters and their
coecients of variation as they get smaller with the number of monitoring
days
The graphs are very similar to those seen in the analysis of Bergman's
model. The inuence of the number of days, especially when it goes from one
to two is very important, and no negligible, both in the case of experiment
and no experiment design.
The inuence of the experiment design in the identiability of the model
can clearly be seen in Figure 6.17, where it is shown that experiment design
improves identiability dramatically. In this case, it can be observed that
identiability of almost all the parameters rises enormously, getting their
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Figure 6.16: coecients of variation of modied Panunzi's optimal
parameters for the experiments designed as they get smaller with the number
of monitoring days
coecients of variation divided by two or three. Special cases are the
parameters 1 and 14, whose identiability rises to a smaller extent. This
strange behavior might be explained by the strong correlation between these
two parameters since both of them are very related to the plasma insulin and
its inuence in blood glucose (parameter 1,Kxgl, is the insulin sensitivity and
parameter 14, ke, is the plasma insulin elimination).
These results have yet to be compared to the experiment design results
with the suboptimal set of parameters of modied Panunzi's model. For this
new set of parameters, another experiment design was performed. This set
of parameters was the one that was going to be identied in ambulatory
conditions, because it was physiologically interesting for the reasons stated
before. It is expected that the results are not radically dierent to anything
already seen, and this experiment design is going to be considered as a whole
new design as it was a completely new model.
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Figure 6.17: Identiability of the optimal set of parameters of modied
Panunzi's model before and after the experiment design for the case of a
three meals monitoring
The results of the experiment design for the case of a single day of
monitoring are shown in Table 6.14.
Experiment Units Day 1
τ minutes -18,41
Meal gr CHO 100
Bolus IU 10
Table 6.14: Experiment designed for modied Panunzi's model considering
one day of monitoring and the suboptimal set of parameters
It shows again the administration of the bolus in advance to the meal
time. This sort of therapy seems to be the most ecient way to extract
information for the model, regardless the model being identied.
The response of the model to that therapy is show in Figure 6.18,
which is actually exactly the same gure as the model's result with the
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optimal parameters' set. The same model and the same input must give
the same output. The small dierences that can be found are related to
small dierences on the convergence of the optimizer, that are translated to
small dierences in the input of the model.
Figure 6.18: Modied Panunzi's model response to the proposed experiment,
with the suboptimal set of parameters, for 1 day
The results for the two days experiment are shown in Table 6.15.
A new type of experiment is designed in the rst day. There is the delay
again in the insulin dose, but now the meal is as big as it gets, and the insulin
is not exactly proportional to the meal size. This can be a problem, because
the insulin control may not be accurate.
The model response can be seen in Figure 6.19.
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Experiment Units Day 1 Day 2
τ minutes 19,49 -17,50
Meal gr CHO 100 100
Bolus IU 8,16 10
Table 6.15: Experiment designed for modied Panunzi's model considering
two days of monitoring and the suboptimal set of parameters
Figure 6.19: Modied Panunzi's model response to the proposed experiment,
with the suboptimal set of parameters, for 2 days
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It can be observed in the rst day of simulation how the delay in the
insulin administration and the big size of the meal make the blood glucose
to rise up to the limit of safety, and then drop down to the lower limit.
Probably, a bigger insulin dose would lead to hypoglycemia, and lower meal
sizes will not make the Dalla Man model's identiability large enough. It is
worth remembering that the whole gastrointestinal model is being identied
in this case.
The experiment results for a three days experiment are shown in Table
6.16, and the model's results are drawn in Figure 6.20.
Experiment Units Day 1 Day 2 Day 3
τ minutes -18,26 18,77 -17,96
Meal gr CHO 99,62 99,56 99,18
Bolus IU 9,98 8,10 9,91
Table 6.16: Experiment designed for modied Panunzi's model considering
three days of monitoring and the suboptimal set of parameters
Again, the advance of the insulin bolus is repeated, as it is the most
ecient way of getting information from the signal. The day in the middle is
the delayed insulin prole as described in the previous experiment. It can be
observed again that the order of the days does not matter, and having the
delayed insulin therapy in the rst, the second, or the third day, will have
the same result.
The last experiment designed, the one for four days of monitoring, is
shown in Table 6.17, and the simulation is in Figure 6.21.
Experiment Units Day 1 Day 2 Day 3 Day 4
τ minutes 19,42 -17,77 -17,54 -17,69
Meal gr CHO 100 100 100 100
Bolus IU 8,16 10 10 10
Table 6.17: Experiment designed for modied Panunzi's model considering
four days of monitoring and the suboptimal set of parameters
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Figure 6.20: Modied Panunzi's model response to the proposed experiment,
with the suboptimal set of parameters, for 3 days
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Figure 6.21: Modied Panunzi's model response to the proposed experiment,
with the suboptimal set of parameters, for 4 days
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In this last experiment, the administration of the insulin dose is advanced
three times, while the delay is applied only once. Given that with this set
of parameters, Dalla Man's model is being completely identied, and that it
is assumed that the delays on insulin bolus are associated with the better
identiability of the gastrointestinal system, on can only assume that the
importance of identiability of Dalla Man's model to the total identiability
of the model gets to a relative minimum with only one day of insulin delayed.
As a summary, the identiability of the models, increase with longer
periods of monitoring (Figures 6.22 and 6.23), regardless of the experiment
design.
Figure 6.22: Modied Panunzi's suboptimal parameters and their coecients
of variation as they get smaller with the number of monitoring days
The only dierence (they look mostly the same) in this gures is the level
in where the coecients of variation move. The comparison between the
cases of before and after the experiment design can be observed in Figure
6.24 for the 3 days case.
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Figure 6.23: coecients of variation of modied Panunzi's suboptimal
parameters for the experiments designed as they get smaller with the number
of monitoring days
Figure 6.24: Identiability of the suboptimal set of parameters of modied
Panunzi's model before and after the experiment design in a three meals
monitoring
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As can be observed, the experiment design increases the overall
identiability of the model with the experiment design, except for two Dalla
Man's model parameters, the 5th and 6th. Those parameters are Kabs and
Kmax, and both of them express ow rates of glucose in the gastrointestinal
tract. It is likely that they are very correlated. The rest of the coecients of
variation are maintained relatively high probably due to the overlapping of
the dynamics derived from those two parameters. This phenomenon would
explain the fact that only one day of the experiment (even in a 4 days
monitoring) is utilized for individually identify the gastrointestinal model
delaying the insulin bolus.
6.5 Discussion and clinical protocol
The results of the experiment design do not have to be taken literally in
practice. The assumptions made when using each model and the nominal
parameters of it have great importance on the results of the experiment
design. However, from a practical point of view, experimenting with several
dierent models allows us to draw some general qualitative conclusions. That
is why the design has been repeated several times in this thesis. Qualitative
and common characteristics of the experiments designed are going to be
extracted in the next lines, trying to get the most important features needed
in a monitoring for the good posterior identication of a patient, regardless
of the model used.
There are two dierent single day experiments. The experiment design
aims to separate the dynamics of the sub-models for a better identication.
In one case insulin dose is given without meal perturbation, limited by the
hypoglycemia constraint, in order to obtain information of the subcutaneous
insulin model. The other situation is exactly the opposite; a meal is given
while the insulin dose is delayed limited by the hyperglycemia constraint.
During this time, the intestinal absorption model is the only one acting on
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the output signal. Optimal experiment design forces the model to move in all
the range of operation set in order to preserve patient's safety, thus extracting
more information out of the data.
The application of the designed experiment in ambulatory conditions is
not straightforward. In the optimal experiment design the patient (virtual) is
supposed to be stabilized and in situation of normal glucose. In the real life,
even in the fasting state, patients may not be under steady state conditions,
with glucose values in any glycemic range. Under these circumstances,
application of the optimal experiment design to the clinical setting requires
some cautions. Indeed, if the patient is hyperglycemic at the beginning of the
experiment, delaying more than two hours the insulin dose can be dangerous
for the patient's health, with extremely high glucose values. On the other
hand, if the patient is hypoglycemic, administrating an insulin dose without
carbohydrates ingestion can lead to severe hypoglycemia.
Therefore, an adaptation of the optimal experiment design to the initial
metabolic state of the patient is proposed. If the patient has a blood glucose
level over 150 mg/dl or in the 100-150 mg/dl range with an increasing trend
(hyperglycemic risk), the insulin bolus is given followed 30 minutes later by
a 100 grams meal. If the glucose level is below 100 mg/dl or in the 100-
150 mg/dl range with a decreasing trend (hypoglycemic risk), a 40 or 60
(patient's choice) grams meal is given and the insulin dose administration is
delayed 120 minutes. In both situations the dose to be administered is the one
recommended to the patient, depending on the size of the meal and his/her
usual insulin-to-carbohydrate ratio. The patient can choose among three
menus with the same relative nutritional composition. With this protocol the
separation of dynamics is achieved, while minimizing risks for the patients.
The protocol has been approved by the Ethical Committee of the
Clinic University Hospital of Valencia and clinical trials are currently being
performed for validation of the identication procedure. Patients are
currently being monitored during two weeks, with a wash-up week in between,
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and instructed to follow the protocol dened by the experiment design. In
a week, three days are used for identication and three for validation, as it
was scheduled due to restriction of the lifetime of the sensor utilized.
Some preliminary results of monitoring, identication and validation






Clinical validation of experiment design with modied Panunzi's model
started in the Clinical University Hospital of Valencia the 20th of January,
2010, with the rst week of monitoring of a diabetic patient.
Every week of monitoring is organized in the following way:
• Day 1 - Insertion of the continuous sensor. Warm-up period to ensure
stabilization of the sensor signal.
• Days 2, 3 and 4 - Identication period. At the patient's usual lunch
time, the patient is instructed to follow the experimental protocol
described in the previous chapter. In particular, they are advised to
avoid any snack or additional insulin administration during the ve
hours period following the meal, unless some harmful event would occur
to the patient, such as an hypoglycemic event.
• Days 5, 6 and 7 - Validation period. The patient follows her/his usual
treatment without any shift of insulin administration, for validation
167
purposes. The menus from which the patients can choose are the same
of the identication period, reducing variability related to the meal
composition.
The results that are shown next are only preliminary results, and only are
reviewed qualitatively for identication purposes. The complications related
to experimental data acquisition in diabetic patients are highlighted in every
case. So far 5 patients have been monitored, some of them several weeks,
and others only 1 week. The maximum number of weeks monitored in the
same person is 4.
The results shown next consist of two graphs for each week of monitoring:
the rst one are the three meals of the identication period; the second graph
is the data corresponding to the validation period, considering uncertainty.
The response of the model considering uncertainty is calculated by means of
interval analysis of the models explained before, and only 2 parameters are
being considered uncertain:
• Meal size is considered with a 10% of uncertainty. Meal size is
not a parameter of the model, but the estimation of the amount
of carbohydrates is usually done by the patient, incurring in severe
approximations of the right size of the meal being ingested.
• Kxgl, or insulin sensitivity, is considered to vary in a 20% from its
identied value. Indeed, in daily life of people with diabetes insulin
sensitivity can change signicantly depending on many factors such as
the intensity of physical activity, health conditions, emotional stress,
and so on.
If the uncertainty considered are to be dierent in any case, it will be
explicitly stated. Based on each patient home glucose monitoring diary,
if high variability in the meal size is observed, or if unexpected/unplanned
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events potentially inuential for Kxgl are reported, then greater variability
has been considered to obtain more robust predictions.
Considering uncertainty for validation purposes is one of the main
outcomes of this thesis. In the diabetes context, great variability of
the parameters identied is expected. The ambulatory conditions on
which the monitoring of patients happen, makes the data to be extremely
noisy, with unplanned events and errors in the treatments proposed. The
combination of these sources of error invalidates identications performed
almost immediately.
There exist several ways to overcome the lack of delity of the
identication to the real process. In the continuous (real-time) control
of diabetes, adaptive algorithms for control seem to be necessary in
order to follow the patient parameters variations. Consecutive model
identications may be performed every day improving data tting and
prediction capabilities of the model. In an o-line study of several days like
the one of this thesis, only one identication may be performed, considering
the limitations exposed before (same meal composition, same meal time...).
The variations of the patients in this case cannot be copped with successive
identications or adaptive algorithms, but robust controllers have to be
developed. Robust control needs of a quantication of the error expected on
the model, and this can be done by considering uncertainty on the parameters
identied.
Each one of the following sections corresponds to a dierent patient
and his/her number of weeks of monitoring. The patients are designated
anonymously with their initials.
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7.1 Monitored Data from Patients
7.1.1 Patient HMJ
HMJ was monitored during 4 weeks (not consecutive), following the protocol
described explicitly. First week's identication period is shown in Figure 7.1.
Each day's postprandial period of 5 hours is separated by vertical dashed
lines.
Figure 7.1: HMJ's rst week's identication period
The rst day's meal the patient ate the meal conguration 1. In this
conguration, the insulin bolus was given 30 minutes before the meal time (as
shown in the gure), and the meal size was 100 grams. The second and third
days the patient ate the meal conguration 2. In this second conguration
the insulin bolus is delayed 120 minutes and the patient is given to choose
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from a 40 or 60 grams meal. It's worth remembering that regardless the meal
size, the meal composition remains constant. The same meal conguration
is used for all the patients.
There is a clear dierence between the dynamics of the second and third
days, and the rst one, as the experiment design predicted. The rising of
glucose after the meal is though completely faded by the insulin dose. The
last day shows an illustrating example of the problems that can be found
durign experimental data acquisition. The black dots shown in the graph are
the capillary measures of glucose performed by the patient and introduced in
the CGMS as calibration points. In the middle of the third day, the patient
consecutively introduced two very separated calibration points in the sensor,
misleading the signal of the sensor, and consequently, polluting the source of
the identication. Despite the human errors related to the monitoring, the
identication can be considered successful. First week's validation period is
shown in Figure 7.2.
The ideal situation would be to have the continuous line of the monitor
completely covered by the band of prediction of the model. In practice this
would almost never happen. In the case of the rst week of validation for
HMJ, the CGMS was very noisy (specially the third day), and the validation
was not satisfactory. The lack of similarity in the rst day can be attributed
to a even bigger (than 20%) variation of insulin sensitivity, making the patient
more resistant to insulin, and making blood glucose to be higher at any time.
The second day presents a delay of 100 minutes in the glucose absorption,
which is not possible to simulate with the model. The third day noise makes
the data unreadable.
The second week's identication period is shown in Figure 7.3.
The data has been tted with great success in this case. The rst and
second days correspond to meal conguration 2, and the third day meal
conguration 1 was eaten. The second day of identication shows an error in
the calibration data of the sensor. There is a point of capillary glucose of 119
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Figure 7.2: HMJ's rst week's validation period
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Figure 7.3: HMJ's second week's identication period
173
mg/dl, while the sensor is more than 100 mg/dl above that level. Given that
no correction was done by the CGMS of the signal of the estimation of the
blood glucose, it was assumed that the monitor discarded that calibration
point. Other outlying calibration point occurs in the third day, but in this
case the error is smaller (50 mg/dl).
The validation days for that week are shown in Figure 7.4.
Figure 7.4: HMJ's second week's validation period
The rst day of validation is wonderfully tted, but the other two days
show longer absorption proles than expected, and the patient has higher
blood glucose concentrations than the predicted by the model, despite the
fact that the ve hours prediction was within boundaries in all the cases.
The third week's identication period of monitoring can be seen in Figure
7.5.
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Figure 7.5: HMJ's third week's identication period
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In this case the three meals eaten were those of conguration 2. The
tting is quite satisfactory, but it tends to predict hypoglycemias in a ve
hours time that usually do not happen. The third day tting is perfect. The
case of a three repeated meals with the same conguration does not follow
the experiment design ndings, and as such, not very good identication is
expected, and the validation period should not be very well predicted.
The validation meals and their postprandial periods can be seen in Figure
7.6.
Figure 7.6: HMJ's third week's validation period
The Second day is very well predicted, the rst one only in the rst two
hours, and the third day prediction is not good. The rst and third days
predictions end in ctional hypoglycemia, while the patient is actually in
the safe area. This fact makes the model to predict hypoglycemias in the
fourth or fth hours of the postprandial period. This is an error introduced
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by the lack of conguration 1 meals in the identication period, and should
be avoided.
The fourth day's identication meals are shown in Figure 7.7.
Figure 7.7: HMJ's fourth week's identication period
The rst and the second days correspond to conguration 2 meals, and
the third day a conguration 1 meal was eaten. The patient ate the same
the rst and second days, and a clear dierence in the monitor's prediction
can be seen. Model's tting is quite good for both days, and a little worse
for the third day, but yet satisfactory.
The validation days can be seen in Figure 7.8.
The rst day of validation is very well predicted. The second day, the
CGMS had a strange behavior, not caused by any erroneous calibration
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Figure 7.8: HMJ's fourth week's validation period
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points as before, but maybe because of external cause related to the patient.
The third day's prediction is quite good, despite the fact that the prediction
in a 5 hours horizon is overestimating blood glucose.
7.1.2 Patient ACN
This patient was the second one to be monitored, and the last of the patients
that were subjected to 4 weeks of monitoring. The rst week's identication
meals are shown in Figure 7.9.
Figure 7.9: ACN's rst week's identication period
The two rst meals are of conguration 1, and the third day lunch was a
conguration 2 meal. The dynamics observed describe very well the dierence
on the conguration of the meal. In the case of conguration 1, blood glucose
does not rise after the meal time as it does in conguration 2 meal. This
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happens because, in conguration 1 meals, the peak of insulin concentration
in plasma occurs at the same time that the meal starts being absorbed (45-
75 minutes), which causes the blood glucose to be constant at any time.
Actually, a tighter control of blood glucose is observed in conguration 1
meals than in standard treatments, or in conguration 2 meals, where there
is a period of 2 hours without any control at all.
A clear dierence in the dynamics of blood glucose can be see by
comparing the two rst days. The rising tendency in 5 hours after the meal
in the rst day is completely the opposite than it is in the second day, where
the tendency is to drop down. This dierence can occur due to variations
in the insulin sensitivity of the patient or in other physiologic parameters
(metabolic condition of the patient), or maybe due to a sensor dysfunction.
Indeed, the rst day a calibration point was introduced in the post-prandial
period, whereas in the second no calibration was performed. This may have
aected the sensor's tendency.
The validation period is shown in Figure 7.10.
Validation is very satisfactory. In the last day, prediction is good up to
the fourth hour, where the tendency of the blood glucose is the opposite to
the predicted by the model. This corresponds to the same situation observed
during the identication days, even with the presence of a calibration point
at the end of the third day. The causes can again be various, such as a the
eect of that calibration point, or maybe some dierent conditions of the
patient.
The second week's identication period is shown in Figure 7.11.
In this second week of monitoring, the patient ate two conguration 1
meals in the rst two days, and a conguration 2 meal in the last day. The
tting is very satisfactory, specially in the rst and third days.
The validation period is shown in Figure 7.12.
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Figure 7.10: ACN's rst week's validation period
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Figure 7.11: ACN's second week's identication period
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Figure 7.12: ACN's second week's validation period
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The model seems prone to predict hyperglycemias in a ve hours time
lapse, but it is usually correct in its prediction. The exception is the second
day of validation, in which the tendency is completely dierent to the other
days.
The third week's monitoring results and tting are shown in Figure 7.13.
Figure 7.13: ACN's third week's identication period
The patient repeated three times the conguration 1 meal in this case.
This is detrimental to the model identication shown by the experiment
design, but still, the tting is very good. It is very interesting to see that,
despite the three meals were identical in composition, the absorption of
glucose in the rst day is much smaller (or slower) than in the other two
days, causing a lower fall in the blood glucose.
The validation period for this third week is shown in Figure 7.14.
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Figure 7.14: ACN's third week's validation period
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Validation is not very good in this case. Only the second day is included
in the band of the simulation of the model. The other two days describe
dynamics very dierent to the predictions of the model. These problems in
the validation may be caused by the fact that only conguration 1 meals
are identied in the identication period. This can cause problems in
identiability of the model, as it has been proven in simulation, but also,
it the three meals of the identication period follow similar dynamics, the
identication of the postprandial model will give a model that mimics that
dynamic, and no other. This is overtting the data of the experiment. For
example in the present case, all the days of identication have the tendency
of rising the blood glucose at the end of the postprandial period. The
model imitates this behavior, even in the case of normal treatments, which
is obviously not a physiological behavior of the patient.
The fourth week of identication is shown in Figure 7.15.
The rst day the patient ate a meal of conguration 1, and two
conguration 2 meals the second and third days. Data tting is very good
for the rst and third days, but decient in mimicking the dynamic and the
5 hours prediction of the second day.
The validation is shown in Figure 7.16. This validation was done
increasing the uncertainty of the meal to a 20% of the original value, and a
30% in the insulin sensitivity, as explained before.
The bigger uncertainty in the parameters creates broader bands in the
model simulation. The validation of the second and third days is successful,
but the rst day's tendency is completely dierent. Also, there is a ctional
peak in the rst day monitoring, caused by an error in the sensor.
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Figure 7.15: ACN's fourth week's identication period
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Figure 7.16: ACN's fourth week's validation period
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7.1.3 Patient VMD
The third patient monitored, VMD, has been only monitored for one
week, and is still being monitored. The only week of monitoring, and it's
identication period is shown in Figure 7.17.
Figure 7.17: VMD's rst and only week's identication period
The patient ate a conguration 1 meal the second day, and two
conguration 2 meals the other days. The data tting is pretty good for
the rst two days, and the dynamics are well identied, even though in the
third day the peak of glucose is much higher in the monitor than in the
prediction of the model.
The patient overcharged the sensor with calibration points, like in
the second day, in which there are 3 consecutive capillary measurements,
causing corrections in the signal, and disturbing the dynamics of the sensor
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algorithms. But despite that, the results are satisfactory.
The validation period is shown in Figure 7.18.
Figure 7.18: VMD's rst and only week's validation period
Hyperglycemia is predicted by the model at a ve hours time in all the
cases. The second and the third days are tted quite well, and the rst one,
in the rst two hours, is well predicted too. The inuence of unexpected
calibration points is clearly seen in the rst and the second days. The
tendency of the signal is clearly modied at the time of the calibration
measurement in order to adjust to that data point, and that makes the signal
of the sensor to get out of the band predicted by the model.
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7.1.4 Patient SAR
Patient SAR was the fourth patient to be monitored, and only one week has
been monitored so far. More monitoring week are scheduled in the following
months. The identication period is shown in Figure 7.19.
Figure 7.19: SAR's rst and only week's identication period
The tting of the model is very unsatisfying. It is expected the
validation to be worse. The causes can be various, such as invalid calibration
points, extreme noise inuence, or bad use of the monitor from the patient.
Especially bad is the last day of tting, predicting a drop of the blood glucose
down to 100 mg/dl, and the patient being actually in a level of 200 mg/dl.
The validation is shown in Figure 7.20.
The rst day the patient's glucose rises up to 350 mg/dl, even with the
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Figure 7.20: SAR's rst and only week's validation period
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traditional treatment, and the model is not able to predict that behavior.
The other two days of validation are poorly validated. The last day the
patient stopped the monitor in the fourth hour of the postprandial period,
leaving the last day of validation without all the data required.
7.1.5 Patient PGV
Last patient in the study so far was PGV, being monitored only for one
week. The results of the monitoring are shown, for the identication period,
in Figure 7.21.
Figure 7.21: PGV's rst and only week's identication period
The patient ate two conguration 1 meals, the rst and the third days
of the identication period, and a conguration 2 meal the second day. The
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tting of the second day is very good, but the tendencies in the rst and the
third days in the last hour of the postprandial period are not well imitated.
The validation period can be seen in Figure 7.22.
Figure 7.22: PGV's rst and only week's validation period
Validation, despite having broad bands for the simulations, is quite poor.
The second day the calibration point seems to aect the sensor signal once
again. Also, the behavior of the patient in the last hour, in which the glucose
seems to start rising, is not reproduced by the model. In the fourth or fth
hour, the digestive process is likely to be nished, and as such, no income of
glucose from the intestine is happening. Plus, the insulin bolus is supposed
to be totally absorbed at that time. That tendency of increasing glucose
seen in almost every day of monitoring have to be then caused by a lack
of basal insulin in the patient in the postprandial period. This does not
excuse, though, the bad identication of this patient in particular, but it
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shows how comparing the results of an identied model can be benecial for
understanding the metabolic state of the patient and his/her treatments.
7.2 Discussion
The rst conclusion drawn out of the rst weeks of monitoring is that the
experimental factor is the most relevant issue, moreover when speaking of
real patients. The importance of following the experimental design should
be clearly explained to the patients, who may be also advised to report any
deviation from the protocol. This is clearly shown in the patients with more
than 1 week of monitoring. In the rst week, many errors are committed
by the patient, such as wrong calibration points, stopping the insulin pump
at the wrong moment, or administering the next insulin bolus before the
postprandial monitoring ends. Those problems are less frequent when the
patient feels familiar with the device and also due to the identication and
elimination of the most common errors (by instruction to the patients) by
the clinical sta.
Experimental design and identication from real data really helps
understanding the model used for simulating patients. Very complex models
were discarded from the beginning of the experiment for practical reasons in
the implementation and lack of identiability. However, there are dierent
behaviors that the simpler models can not mimic. Independently identify
the dynamics of those behaviors, and reecting them into the equations of
the model is the aim of modeling. It is not possible to do it without the
experimental experience of observing the monitoring and identication of
the postprandial responses of the patients.
The identication process has remained unchanged for all the patients
analyzed. The identication process might be improved by adapting it
to each case independently. Also, it is possible by varying the matrix
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of weighting Qi, as seen in equation 3.1 to adjust the model to better
conditioned periods of time. This way, the noisy data periods can be avoided
to be tted, or maybe the data can be tted better in the early hours of the
postprandial period rather than the last hours. It makes sense to t better
the periods in where only one sub-model is being perturbed, like for example,
in the case of advancing 30 minutes the insulin bolus, adjusting better those
30 minutes.
As a nal remark, the identication is satisfactory. Data tting is usually
excellent. The validation period is trickier to simulate for the current models
in literature. Nevertheless, in many cases, two out of three postprandial
periods were described by the identied model of the same patient, and in





Much work has already been done in identication and modeling for diabetes.
This thesis deepens in the understanding of the models and their capacity
of reproducing the physiology of a diabetic patient. Several models where
analyzed, a new version of an existing model was proposed and model
identication was performed following a protocol designed for maximizing
the information to be extracted. In this chapter, the achievements of this
thesis will be reviewed, and a list of future items of pending work will be
discussed.
8.1 Analysis of the results
The work performed in this thesis was exposed in detail in chronological
order. The work performed rst was exposed rst, and the latest work in the
last chapters. For the nal analysis of the results, a dierent point of view
may help to summarize the ndings of the thesis.
From the point of view of the models analyzed, there were three of them
tested:
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1. Cobelli's model - The rst model tested for identiability in
experimental data was the model accepted by the FDA to simulate
diabetic patients. The model was tested in a whole day of monitoring,
and validated in the next two following days. The results with the
model and the data used were very bad. Out of 22 patients, only 2 were
tted successfully for a whole day of monitoring, and no validation was
successful. The model was discarded of use due to identiability issues.
2. Bergman's model - The same data with which Cobelli's model was
tested was used to test the Bergman model. The scenario was dierent,
and a postprandial approach was used, trying to identify only using
the 5 hours of monitor data after the meal intake. The data tting was
successful for only one patient, and the validation with other meals
failed. The set of data used for identication was discarded as a
consequence of that failure raising the need of an optimal experiment
design. Bergman's model was also used for designing experiments in
order to obtained better quality data.
3. Panunzi's (modied) model - A critical review to Bergman's model
dynamics proved it unable to simulate some physiological features of
real diabetic patients, leading the author of this thesis to modify a
third model (Panunzi's model), to adapt to those dynamics. This
third and denitive model was used for designing experiments, and
also for identication of the patients monitored in those experiments,
with better results than the identications performed Cobelli's model.
Cobelli's model was proven to be unreliable to t a whole day in a
diabetic patient's life. The computational cost of the solvers when working
with this model was another cause to discard using it. Plus, the model was
not identiable in most of its parameters. The rest of the models used are
very light in computational terms. The same solver, working on Bergman's
equations instead of Cobelli's was twice as fast.
Computational cost is an issue that has hardly been mentioned on this
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thesis, but in practice it is one of the biggest drawbacks for the eciency
and implementation of the algorithms. Global optimization methods take
thousands of callings to the function being optimized to get to a solution. If
the function being optimized is the glucose model, like in the case of a model
identication, and if the model evaluation takes around 100 miliseconds, an
average identication of the model will take about 1 hour. That is quite a
heavy computational cost, but it can get worse. In the case of the experiment
design, the cost function is not the glucose model, but the determinant of the
FIM. The evaluation of the information matrix involves algebraic calculations
and evaluations of the actual glucose model; depending on the number of
parameters being varied it can make from 10 to 25 evaluations of the model.
Being the objective function much more complex than the glucose model
the optimization required for the experiment design uses many evaluations
of the cost function, from one hundred thousand up to a million function
evaluations. Considering the same model evaluation cost as before, the
average experiment design will take 9 days to be nished.
Many implementation problems were not described in the thesis report.
The computational cost was a constant problem, and many dierent
implementations of the algorithms were tested. Starting with conceptual
Matlab's Simulink diagrams for the glucose models, the programs were later
implemented in Matlab code, and then in C programming language, speeding
up the function evaluation many times.
The outcomes of the thesis are various:
1. A complete review of the models in literature was done. Identiability
studies on the most relevant models were performed.
2. A new model of endogenous glucose was proposed to better mimic the
observed behavior in experimental data
3. Experiments were designed to achieve a better identiability for
diabetes models. A clinical protocol was dened to adapt the results
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of the experimental design to the clinic.
4. Experiments of continuous home postprandial monitoring were
conducted following the directions set by the experiment design.
5. Validation of the identications were performed considering intra-
patient variability.
Of special importance are the currently ongoing experiments being
performed with real patients. Apart from the current experiments, the work
described in this thesis has led to many open projects, or lines of research.
In the next section the future work (currently being developed), and further
ideas for the situations explained in this thesis will be explained.
8.2 Future work
A list of key points in the future work related to this thesis is now shown as
the nal contribution of this thesis:
1. Analysis of the results. Most of the results shown in this thesis are
only studied qualitatively. Deep data analysis of these results still has
to be done. Some tasks to be performed about this matter are:
• Statistical validation: The experiment design still has to be
statistically validated. Preliminary results of the application of
the experiment design have been shown in this thesis, but more
monitoring weeks have to be added to the work already done, and
statistical results of the identications have to be shown. The
identiability of the model being identied have to be calculated,
and compared with its identiability without the application of the
experiment design, expecting better condence intervals for those
parameters identied. Parameters CVs will not be comparable to
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those already shown in this thesis because those are calculated
based on the nominal values of the parameters, and the validation
have to be made based in the parameters already identied.
• Repeatability: The monitoring periods identied have to be tested
for repeatability in the same period. The same patient in two
consecutive weeks can have very dierent behavior, and this have
to be reected in the model's parameters. The variations between
those parameters will give an idea of how much the model can t
the person instead of tting the situation.
• Comparison of models: Every tested model have to be tested as
a predictor of the glucose state. The prediction horizon of each
identied model have to be tested to see if physiological models
have prediction advantages over other sorts of models.
2. Identication improvement. Identication of the proposed model
has to be improved. Identiability has been deeply studied, but the
process of identication has not been extensively reviewed. Some
feasible improvements to the identication process are:
• Improvement of data: Treatment of the data to be tted is critical
for the success of the identication. Currently, the model output is
being t to monitor data, but much more data is available in other
formats, that may be relevant for the model identication. The
calibration points, which are blood glucose direct measurements,
should be perfectly tted, and may enter cost function of the
optimization in the future. The problem of adding those points
in the identication to be tted is that they are an input that the
patient have to register in the monitor's log, and patients make
lots of errors. That is why along with the calibration points, there
has to be some fail detection system, to discard outliers in the
capillary measurements or in the monitor signal.
• Weight matrix: More options for improving the identication may
involve to vary the matrix of data weighting Qi, as explained
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earlier in the thesis. One may try to better ts some sequences
of data than others, or maybe to forget about tting some
particularly noisy data periods.
• Faster optimization algorithms: More ecient global optimizers
may help to speed up the identications, helping with one of the
biggest problems of these identications, the computational time.
• Interval identication: In this thesis, the process of identication
was done prior the interval analysis of the model to be used
in validation. These to processes can be mixed into interval
identication. This process identies boundaries of parameters
instead of the actual parameters, including the information of
the patient in the model (just as regular identication does), as
well as quantifying the uncertainty of those parameters identied.
This methodology will avoid the heuristic quantication of the
uncertainty that has been used in this thesis.
3. Modeling: The motivation for the experiment design was to improve
the identication of models, due to the low identiability found up to
that point. Other option to improve the tting is to change the model.
It remains as a to-do task to continue improving the model proposed
in this thesis.
4. Open-loop control: In the validation days of the preliminary
results, model intervals were shown for considering uncertainty. Heavy
mathematical interval theory is behind these interval model simulations
which has not been shown in this thesis. Work on Interval Analysis
(IA) and Set Inversion Via Interval Analysis (SIVIA) has been done in
parallel to this thesis, and all the models used where intervalized, as
explained by Calm et al.[13], for using them with uncertainty.
The set inversion algorithms permit the robust calculation of therapies
basal-bolus for tighter postprandial control, as Revert et al. shown [81]
in silico. This approach requires of an identied model of the patient
to make a good therapy proposal, which relates this thesis' research to
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the work done by Revert et al. The validation of these robust methods
and therapies in a clinical experiment is something never done before.
Some of the identications shown in this thesis will be used for the
in vivo validation of the SIVIA therapy proposals, which will be done
in the Hospital Clinic Universitari of Valencia. The patients will be
monitored, the model identied and used for the calculation of therapies
that happens to be called ibolus therapies. Then the patients will be
treated one day with the therapy proposed by the algorithm, and other
day with the traditional bolus treatment, being monitored their blood
glucose both directly and via a monitor. This experiment has been
called the ibolus experiment, and it is a very related project to this
thesis work. Improved treatments by means of SIVIA will have to be
analyzed and improved in the future
5. Closed-loop control: It must not be forgotten that the nal objective
for these models and identications is the control of the blood glucose
in a diabetic patient (articial pancreas). The foundations of this work
have been placed, but there still a lot of work to do. Designing the
controllers will be one of the last steps of this project, and probably
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